<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JHC</journal-id>
<journal-id journal-id-type="hwp">spjhc</journal-id>
<journal-title>Journal of Histochemistry &amp; Cytochemistry</journal-title>
<issn pub-type="ppub">0022-1554</issn>
<issn pub-type="epub">1551-5044</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1369/0022155412464638</article-id>
<article-id pub-id-type="publisher-id">10.1369_0022155412464638</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Perspective</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>An Introduction to Proteoglycans and Their Localization</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Couchman</surname><given-names>John R.</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Pataki</surname><given-names>Csilla A.</given-names></name>
</contrib>
<aff id="aff1-0022155412464638">Department of Biomedical Sciences, University of Copenhagen, Copenhagen N, Denmark</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0022155412464638">John R. Couchman, PhD, Department of Biomedical Sciences, University of Copenhagen Biocenter, Ole Maaløes Vej 5, 2200 Copenhagen N, Denmark. E-mail: <email>john.couchman@bric.ku.dk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>60</volume>
<issue>12</issue>
<fpage>885</fpage>
<lpage>897</lpage>
<history>
<date date-type="received">
<day>29</day>
<month>6</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>9</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">The Histochemical Society</copyright-holder>
</permissions>
<abstract>
<p>Proteoglycans comprise a core protein to which one or more glycosaminoglycan chains are covalently attached. Although a small number of proteins have the capacity to be glycanated and become proteoglycans, it is now realized that these macromolecules have a range of functions, dependent on type and in vivo location, and have important roles in invertebrate and vertebrate development, maintenance, and tissue repair. Many biologically potent small proteins can bind glycosaminoglycan chains as a key part of their function in the extracellular matrix, at the cell surface, and also in some intracellular locations. Therefore, the participation of proteoglycans in disease is receiving increased attention. In this short review, proteoglycan structure, function, and localizations are summarized, with reference to accompanying reviews in this issue as well as other recent literature. Included are some remarks on proteoglycan and glycosaminoglycan localization techniques, with reference to the special physicochemical properties of these complex molecules.</p>
</abstract>
<kwd-group>
<kwd>glycosaminoglycan</kwd>
<kwd>polysaccharide</kwd>
<kwd>core protein</kwd>
<kwd>heparan</kwd>
<kwd>chondroitin</kwd>
<kwd>dermatan</kwd>
<kwd>hyaluronan</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Proteoglycans are present in all members of the Bilateria and therefore have a long evolutionary history. Moreover, they are widespread components of most tissues and organs and can sometimes be a dominant component (e.g., in the vertebrate cartilage matrix). Studies of proteoglycans initially focused on this tissue, since the major component, now known as aggrecan (<xref ref-type="bibr" rid="bibr6-0022155412464638">Aspberg 2012</xref>), is abundant and readily purified. However, it is now clear that virtually all extracellular matrices contain proteoglycans, and they are also present in the pericellular matrix of many cell types. Moreover, they are not restricted to extracellular locations, since some are specialized components of membrane-bound secretory granules—for example, heparin and highly sulfated forms of chondroitin are present in the granules of mast cells, other leukocytes, and endodermal and endothelial cells (see <xref ref-type="bibr" rid="bibr86-0022155412464638">Rönnberg et al. 2012</xref>). Several reports also suggest that proteoglycans can become localized in the nucleus, although its functional significance remains unknown.</p>
<p>Given that proteoglycans are ubiquitous in multicellular animals and occur in many tissues in many forms, it is unsurprising that they are ascribed a variety of functions. Some are structural, such as aggrecan and its relatives, others control enzymatic activity, and still others serve as cell surface receptors. In development and tissue repair, proteoglycans may have key roles in controlling gradients and availability of potent growth factors, chemokines, cytokines, and morphogens. The roles are many but incompletely understood. However, interest is increasing in these molecules. Although their structural complexity is considerable, as explained here and in other reviews in this volume, their importance in homeostasis, development, repair, and disease, notably cancer, is apparent. Proteoglycan variation in form and function reaches its peak in mammals where the sophistication of the immune system and variety of extracellular matrices that comprise tissues across this group are underlying factors.</p>
<p>The accompanying series of short reviews on proteoglycans cover a range of topics relevant to mammalian biology and disease. They follow from the Nordic Proteoglycan Workshop held at the Copenhagen Biocenter, University of Copenhagen, on April 16-17, 2012. The workshop was funded, in large part, by the Alfred Benzon Foundation.</p>
<sec id="section1-0022155412464638">
<title>Proteoglycans—What Are They?</title>
<p>By definition, proteoglycans consist of a core protein to which one or more glycosaminoglycan chains are covalently attached. Glycosaminoglycans (GAGs) themselves are unbranched, often long polysaccharides with a repeating disaccharide structure. The number of glycosaminoglycan types is rather few, and their structures are shown in <xref ref-type="fig" rid="fig1-0022155412464638">Figure 1</xref>. Correspondingly, the number of proteins that become substituted with GAGs is also small, and many of these fall into major families. For example, the large hyaluronan-binding (aggregating) proteoglycans, the lecticans (<xref ref-type="bibr" rid="bibr112-0022155412464638">Yamaguchi 2000</xref>), consist of four members, aggrecan, versican, neurocan, and brevican. Aggrecan is the major proteoglycan of cartilage, whereas versican is enriched in large blood vessels. Neurocan and brevican are concentrated particularly in the specialized extracellular matrices of the brain. These have chondroitin sulfate as their major GAG, although aggrecan also possesses keratan sulfate. Versican is subject to alternate mRNA splicing that can give rise to several isoforms, one of which contains no GAGs (<xref ref-type="bibr" rid="bibr57-0022155412464638">Lemire et al. 1999</xref>). A quite different family of proteoglycans is the syndecans, which are transmembrane receptors capable of signaling independently or in combination with other receptors, such as fibroblast growth factor receptors or the cell adhesion receptors, integrins (<xref ref-type="bibr" rid="bibr22-0022155412464638">Couchman, 2003</xref>; <xref ref-type="bibr" rid="bibr24-0022155412464638">2010</xref>; <xref ref-type="bibr" rid="bibr67-0022155412464638">Morgan et al. 2007</xref>; <xref ref-type="bibr" rid="bibr70-0022155412464638">Murakami and Simons 2008</xref>). <xref ref-type="table" rid="table1-0022155412464638">Table 1</xref> summarizes some of the major groups of proteoglycans. It is likely that all mammalian extracellular matrices and all cell surfaces, with the exception of erythrocytes, possess one and, frequently, multiple proteoglycans.</p>
<fig id="fig1-0022155412464638" position="float">
<label>Figure 1.</label>
<caption><p>Composition of the glycosaminoglycans. Heparan sulfate (HS), chondroitin sulfate (CS), and dermatan sulfate (DS) all have a common stem oligosaccharide consisting of xylose and two galactose residues followed by a single glucuronic acid. Heparan sulfate (and the related highly sulfated heparin) then consists of a repeating disaccharide of <italic>N</italic>-acetylglucosamine and glucuronic acid. Subsequently, some of the <italic>N</italic>-acetylglucosamine is deacetylated and <italic>N</italic>-sulfated (NS). This usually occurs in blocks along the chain. These sulfated domains then undergo uronic acid epimerization, converting glucuronic acid to iduronic acid, some of which is then 2-<italic>O</italic>-sulfated (2S). Further modifications are 6-<italic>O</italic> and (rarely) 3-<italic>O</italic> sulfation of the hexosamine residues. In heparan sulfate, these modifications do not go to completion but culminate in domains of high sulfation (often referred to as NS domains) interspersed in regions of low or no sulfation (NA domains). Zones of intermediate sulfation can occur at the boundaries between these two extremes (NS/NA). Chondroitin and dermatan sulfates are similar: both consist of a repeating disaccharide of <italic>N</italic>-acetylgalactosamine and glucuronic acid. However, dermatan sulfate, by definition, has some of the uronic acid epimerized to iduronic acid by epimerase enzymes. Some of this iduronic acid can be sulfated at the 2-<italic>O</italic> position (2S). In the example shown here, both the CS and DS chains are sulfated at the 4-<italic>O</italic> position on the <italic>N</italic>-acetylgalactosamine (4S). However, chondroitin can be unsulfated or 6-<italic>O</italic> sulfated, and commonly a chain can contain more than one type of sulfation. Oversulfated forms of CS are known; for example, chondroitin sulfate E contains <italic>N</italic>-acetylgalactosamine sulfated at both the 4- and 6-<italic>O</italic> positions. Oversulfated forms of DS are also known. Hyaluronan (HA) comprises <italic>N</italic>-acetylglucosamine and glucuronic acid in a repeating disaccharide and may form chains of Mr = 1 × 10<sup>6</sup> or more. It is synthesized at the cell surface and is therefore not modified by, for example, sulfation. Keratan sulfate (KS) consists of repeating disaccharides of galactose and N-acetylglucosamine, both of which can be 6-<italic>O</italic> sulfated.</p></caption>
<graphic xlink:href="10.1369_0022155412464638-fig1.tif"/>
</fig>
<table-wrap id="table1-0022155412464638" position="float">
<label>Table 1.</label>
<caption><p>Characteristics of Some Human Proteoglycans</p></caption>
<graphic alternate-form-of="table1-0022155412464638" xlink:href="10.1369_0022155412464638-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Proteoglycan</th>
<th align="center">Core Protein Size, kDa</th>
<th align="center">Type of GAG Chains</th>
<th align="center">Human Chromosome Localization</th>
<th align="center">Tissue Location</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5"><bold>Glypicans</bold></td>
</tr>
<tr>
<td>Glypican 1</td>
<td>56</td>
<td>HS</td>
<td>Chromosome: 2 location: 2q35-q37</td>
<td>GPI-anchored cell surface</td>
</tr>
<tr>
<td>Glypican 2</td>
<td>59</td>
<td>HS</td>
<td>Chromosome: 7 location: 7q22.1</td>
<td>GPI-anchored cell surface</td>
</tr>
<tr>
<td>Glypican 3</td>
<td>59</td>
<td>HS</td>
<td>Chromosome: X location: Xq26.1</td>
<td>GPI-anchored cell surface</td>
</tr>
<tr>
<td>Glypican 4</td>
<td>58</td>
<td>HS</td>
<td>Chromosome: X location: Xq26.1</td>
<td>GPI-anchored cell surface</td>
</tr>
<tr>
<td>Glypican 5</td>
<td>59</td>
<td>HS</td>
<td>Chromosome: 13 location: 13q32</td>
<td>GPI-anchored cell surface</td>
</tr>
<tr>
<td>Glypican 6</td>
<td>58</td>
<td>HS</td>
<td>Chromosome: 13 location: 13q32</td>
<td>GPI-anchored cell surface</td>
</tr>
<tr>
<td colspan="5"><bold>Syndecans</bold></td>
</tr>
<tr>
<td>Syndecan-1</td>
<td>33</td>
<td>HS, CS/DS</td>
<td>Chromosome: 2 location: 2p24.1</td>
<td>Transmembrane, extracellular</td>
</tr>
<tr>
<td>Syndecan-2</td>
<td>23</td>
<td>HS</td>
<td>Chromosome: 8 location: 8q22-23</td>
<td>Transmembrane, extracellular</td>
</tr>
<tr>
<td>Syndecan-3</td>
<td>43</td>
<td>HS, CS/DS</td>
<td>Chromosome: 1 location: 1pter-p22.3</td>
<td>Transmembrane, extracellular</td>
</tr>
<tr>
<td>Syndecan-4</td>
<td>22</td>
<td>HS</td>
<td>Chromosome: 20 location: 20q12</td>
<td>Transmembrane, extracellular</td>
</tr>
<tr>
<td colspan="5"><bold>Lecticans</bold></td>
</tr>
<tr>
<td>Aggrecan</td>
<td>208–220</td>
<td>CS/KS</td>
<td>Chromosome: 15 location: 15q26.1</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Versican (0/1/2/3 isoforms)</td>
<td>373/265/180/72</td>
<td>CS</td>
<td>Chromosome: 5 location: 5q14.3</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Neurocan</td>
<td>145</td>
<td>CS</td>
<td>Chromosome: 19 location: 19p12</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Brevican</td>
<td>96</td>
<td>CS</td>
<td>Chromosome: 1 location: 1q31</td>
<td>Extracellular</td>
</tr>
<tr>
<td colspan="5"><bold>SLRPs</bold></td>
</tr>
<tr>
<td>Decorin</td>
<td>36</td>
<td>CS/DS</td>
<td>Chromosome: 12 location: 12q21.33</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Biglycan</td>
<td>38</td>
<td>DS/CS</td>
<td>Chromosome: X location: Xq28</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Fibromodulin</td>
<td>42</td>
<td>KS</td>
<td>Chromosome: 1 location: 1q32</td>
<td>Extracellular, intracellular</td>
</tr>
<tr>
<td>Lumican</td>
<td>38</td>
<td>KS</td>
<td>Chromosome: 12 location: 12q21.3-q22</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Keratocan</td>
<td>37</td>
<td>KS</td>
<td>Chromosome: 12 location: 12q22</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Mimecan</td>
<td>25</td>
<td>KS</td>
<td>Chromosome: 9 location: 9q22</td>
<td>Extracellular</td>
</tr>
<tr>
<td colspan="5"><bold>Others</bold></td>
</tr>
<tr>
<td>Thrombomodulin</td>
<td>58</td>
<td>CS</td>
<td>Chromosome: 20 location: 20p11.2</td>
<td>Transmembrane</td>
</tr>
<tr>
<td>CD44 (19 isoforms)</td>
<td>37–81</td>
<td>CS/DS</td>
<td>Chromosome: 11 location: 11p13</td>
<td>Transmembrane, extracellular, intracellular</td>
</tr>
<tr>
<td>NG2/CSPG4</td>
<td>251</td>
<td>CS</td>
<td>Chromosome: 15 location: 15q24.2</td>
<td>Transmembrane</td>
</tr>
<tr>
<td>Invariant chain</td>
<td>31</td>
<td>CS</td>
<td>Chromosome: 5 location: 5q32</td>
<td>Cell surface, intracellular</td>
</tr>
<tr>
<td>Neuroglycan-C</td>
<td>120–150</td>
<td>CS</td>
<td>Chromosome: 3 location: 3p21.3</td>
<td>Transmembrane</td>
</tr>
<tr>
<td>Type XVIII collagen</td>
<td>180–200</td>
<td>HS</td>
<td>Chromosome: 21 location: 21q22.3</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Perlecan</td>
<td>400–450</td>
<td>HS</td>
<td>Chromosome: 2 location: 1p36.1-p34</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Agrin</td>
<td>212</td>
<td>HS</td>
<td>Chromosome: 1 location: 1p36.33</td>
<td>Transmembrane, extracellular</td>
</tr>
<tr>
<td>Betaglycan</td>
<td>110</td>
<td>HS/CS</td>
<td>Chromosome: 1 location: 1p33-p32</td>
<td>Transmembrane</td>
</tr>
<tr>
<td>SV2</td>
<td>20</td>
<td>KS</td>
<td>Chromosome: 1 location: 1q21.2</td>
<td>Transmembrane</td>
</tr>
<tr>
<td>Serglycin</td>
<td>10–19</td>
<td>HS/CS</td>
<td>Chromosome: 10 location: 10q22.1</td>
<td>Intracellular</td>
</tr>
<tr>
<td>Endocan</td>
<td>50</td>
<td>DS</td>
<td>Chromosome: 5 location: 5q11.2</td>
<td>Circulating extracellular</td>
</tr>
<tr>
<td>Neuropilin-1</td>
<td>130</td>
<td>HS/CS</td>
<td>Chromosome: 10 location: 10p12</td>
<td>Transmembrane</td>
</tr>
<tr>
<td>Type IX collagen</td>
<td>270</td>
<td>CS</td>
<td>Chromosome: 6 location: 6q12-q14</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Testican 1</td>
<td>48</td>
<td>HS/CS</td>
<td>Chromosome: 5 location: 5q31.2</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Testican 2</td>
<td>45</td>
<td>HS/CS</td>
<td>Chromosome: 10 location: 10pter-q25.3</td>
<td>Extracellular</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0022155412464638">
<p>CS, chondroitin sulfate; DS, dermatan sulfate; GAG, glycosaminoglycan; GPI, glycosylphosphatidylinositol; HS, heparan sulfate; KS, keratan sulfate; SLRP, small leucine-rich family of proteoglycans.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>A few words need to be said about hyaluronan, or hyaluronic acid (HA), as it is also known. This GAG has a deceptively simple composition, yet takes part in a number of essential processes in vertebrate development, repair, and disease. It is absent from invertebrates. However, hyaluronan is not synthesized as part of a proteoglycan (i.e., it is not attached to a core protein). It is synthesized at the cell surface, and three mammalian HA synthases are known (<xref ref-type="bibr" rid="bibr109-0022155412464638">Wang A et al. 2011</xref>). It is therefore released to the extracellular environment without passage through the Golgi. Commensurate with this unique synthetic pathway, HA is not sulfated or otherwise modified at the time of synthesis. It can, however, be modified subsequently by covalent linkage to inter-α-inhibitor (IαI; <xref ref-type="bibr" rid="bibr114-0022155412464638">Zhang et al. 2012</xref>) family members, a group of serine protease inhibitors. The cross-linkage is catalyzed by tumor necrosis factor (TNF)–stimulated gene 6 (TSG-6; <xref ref-type="bibr" rid="bibr90-0022155412464638">Sangaard et al. 2008</xref>), and the complex is anti-inflammatory. Moreover, the HA-IαI heavy chain complex is a major component of the cumulus matrix and is essential for ovulation and fertilization in the mouse (<xref ref-type="bibr" rid="bibr115-0022155412464638">Zhuo et al. 2001</xref>). Hyaluronan can also interact noncovalently with a number of matrix components. It may also be bound at the cell surface by receptors such as CD44. This may be important in enhancing signaling through cell surface growth factor receptors (<xref ref-type="bibr" rid="bibr12-0022155412464638">Bourgignon et al. 2007</xref>; <xref ref-type="bibr" rid="bibr53-0022155412464638">Kim Y et al. 2008</xref>; <xref ref-type="bibr" rid="bibr65-0022155412464638">Misra et al. 2008</xref>). CD44 null mice have a mild phenotype, yet disease models show a role in limiting inflammatory responses (<xref ref-type="bibr" rid="bibr110-0022155412464638">Wang Q et al. 2002</xref>; <xref ref-type="bibr" rid="bibr76-0022155412464638">Ponta et al. 2003</xref>; <xref ref-type="bibr" rid="bibr77-0022155412464638">Puré and Assoian 2009</xref>).</p>
<p>It can be appreciated that the complexity of GAG structures (e.g., heparan, chondroitin, and dermatan sulfate) can only be achieved by organized synthesis and modifications that are controlled by the cell. A large number of transferases and modifying enzymes together have the role of regulating the fine structural properties of the GAGs. The following reviews by <xref ref-type="bibr" rid="bibr56-0022155412464638">Kreuger and Kjellén (2012)</xref>, <xref ref-type="bibr" rid="bibr69-0022155412464638">Multhaupt and Couchman (2012)</xref>, and <xref ref-type="bibr" rid="bibr61-0022155412464638">Malmström et al. (2012)</xref> highlight some of the key issues. Although GAG synthesis (with the exception of HA) takes place in the Golgi apparatus, and all of the enzymes involved are known from many genomes, including human, mouse, and genetic models such as zebrafish, <italic>Drosophila</italic>, and <italic>Caenorhabditis elegans</italic>, the regulation of synthesis remains, for the most part, unknown. Immunocytochemistry is playing a part in tracking where the synthases and transferases are localized in the Golgi, as part of unraveling this complex synthetic pathway (<xref ref-type="bibr" rid="bibr69-0022155412464638">Multhaupt and Couchman 2012</xref>). Heparan sulfate is perhaps the most complex polysaccharide known to date, in terms of modifications by sulfation and epimerization, so it is a challenge to understand how cells regulate its synthesis.</p>
</sec>
<sec id="section2-0022155412464638">
<title>Proteoglycans—Where They Are and How to Localize Them</title>
<p>Immunohistochemistry and immunocytochemistry have been important techniques in discovering the distributions of the proteoglycans. Many core protein antibodies are available, although some are not as specific and high affinity as would be desirable. Caution is needed with a number of commercial antibodies generally (<xref ref-type="bibr" rid="bibr23-0022155412464638">Couchman 2009</xref>; <xref ref-type="bibr" rid="bibr91-0022155412464638">Saper 2009</xref>). It should be pointed out that Western blotting is often part of antibody characterization, but for proteoglycans, this can be challenging because the GAGs may be a dominant physicochemical feature of the whole macromolecule. Some GAGs may be &gt;20 kD in size, and when present in multiple copies on each core protein, the proteoglycan may appear very heterodisperse by SDS-PAGE. Moreover, purifying proteoglycans usually requires some specific methods (<xref ref-type="bibr" rid="bibr46-0022155412464638">Iozzo 2001</xref>) that take advantage of GAG properties, such as anion exchange chromatography or density gradient centrifugation. One way to reduce the heterodisperse nature of the proteoglycan is to remove the GAGs by specific bacterial enzymes, such as chondroitinase ABC or heparitinase. These enzymes can remove most of the corresponding GAG chain, apart from a small carbohydrate “stub” (<xref ref-type="fig" rid="fig2-0022155412464638">Fig. 2</xref>). The core proteins may then resolve as discrete polypeptides. In a similar way, immunohistochemistry for core proteins can also be more complex because of the GAGs. Fixatives, particularly those that precipitate, can cause the GAGs to collapse and mask the core protein. However, it is quite possible to use the same GAG-degrading enzymes to treat paraffin sections, for example, after the antigen retrieval steps. This will remove the GAGs and, in some cases, render the core proteins more accessible to specific antibodies. The GAG-degrading enzymes often require specific buffers that are suggested by the suppliers but are also in the literature (<xref ref-type="bibr" rid="bibr46-0022155412464638">Iozzo 2001</xref>).</p>
<fig id="fig2-0022155412464638" position="float">
<label>Figure 2.</label>
<caption><p>Action of heparinases and chondroitinases on their respective glycosaminoglycans. These bacterial enzymes are eliminases and so, on cleavage of the polysaccharides, create an unsaturated uronic acid residue. One of these units will be present at the end of the carbohydrate “stub” remaining on each core protein. In addition, disaccharides or larger oligosaccharides will be released, each bearing a similar terminal unsaturated uronic acid. (A) There are three bacterial heparinases, I, II, and III, each of which has particular substrate specificity in terms of the heparan sulfate (HS) structure it will cleave. Heparinase III, for example, will cleave at unsulfated regions, and since the region proximal to the core protein is usually of low sulfation, this enzyme will pare back the polysaccharide close to the core protein. As a result of selectivity in heparan sulfate substrates that the three enzymes will cleave, oligosaccharides composed of varying numbers of disaccharide units will be released. To maximize heparan sulfate disaccharide cleavage products, it is common to use all three heparinases synchronously. For simplicity, the infrequent 3-<italic>O</italic>-sulfate modification of glucosamine is not shown. (B) Chondroitinase ABC will cleave chondroitin 4-sulfate (CS-A), dermatan sulfate (CS-B), and chondroitin 6-sulfate (CS-C), whereas chondroitinase ACII, for example, will not cleave dermatan sulfate. Chondroitin 4-sulfate is shown as a substrate in the model with symbols, but chondroitin may be unsulfated, 6-O sulfated, or a combination of these forms. However, in each case, a product with terminal unsaturated uronic acid will result from enzyme cleavage. R—H or SO<sub>3</sub>; R′—COCH<sub>3</sub> or SO<sub>3</sub>.</p></caption>
<graphic xlink:href="10.1369_0022155412464638-fig2.tif"/>
</fig>
<p>The GAGs themselves are not very antigenic, although a number of antibodies, some commercial, are available to them. A series of single-chain antibodies with preference for particular sulfation motifs in heparan sulfate have been reported, for example (<xref ref-type="bibr" rid="bibr106-0022155412464638">van Kuppevelt et al. 1998</xref>; <xref ref-type="bibr" rid="bibr104-0022155412464638">Thompson et al. 2009</xref>). Some antibodies are also available against chondroitin and dermatan sulfates, as well as keratan sulfate (<xref ref-type="bibr" rid="bibr18-0022155412464638">Caterson 2012</xref>). Hyaluronan provides a special challenge, however, as it is difficult to prepare specific antibodies. A review on this area was published recently (<xref ref-type="bibr" rid="bibr29-0022155412464638">de la Motte and Drazba 2011</xref>). The most commonly used technique for this GAG is to use a fragment of the aggrecan core protein, which binds HA with high affinity. A recent study of human skin shows this technique (<xref ref-type="bibr" rid="bibr94-0022155412464638">Siiskonen et al. 2011</xref>). A small number of monoclonal antibodies have particular use for proteoglycans. The bacterial enzymes, such as chondroitinases and heparinases, are eliminases, rather than hydrolases. Therefore, they leave a terminal unsaturated uronic acid after digestion (<xref ref-type="fig" rid="fig2-0022155412464638">Fig. 2</xref>). This in turn is quite antigenic, being a nonnative carbohydrate structure. Some antibodies against chondroitin and heparan sulfate have been characterized with this specific activity (<xref ref-type="bibr" rid="bibr25-0022155412464638">Couchman et al. 1984</xref>; <xref ref-type="bibr" rid="bibr28-0022155412464638">David et al. 1992</xref>). To be used in immunocytochemistry or immunohistochemistry, however, the cells or tissue sections must first be treated with the requisite bacterial enzyme. Moreover, it should be borne in mind that the antibody will not have specificity for the core protein, only the remaining carbohydrate “stub.” This can be useful, for example, in locating all heparan sulfate proteoglycans in a tissue or on a Western blot. A recent study of cutaneous disease provides an example of this technique (<xref ref-type="bibr" rid="bibr51-0022155412464638">Kim JS and Werth 2011</xref>). Such antibodies can be used alongside more traditional, core protein-specific antibodies.</p>
</sec>
<sec id="section3-0022155412464638">
<title>Proteoglycan Distributions</title>
<p>Proteoglycans were first identified as extracellular matrix components, and older histology textbooks referred to <italic>ground substance</italic>, an all-embracing term that included the location of these soluble macromolecules. As with collagens and glycoproteins, the spectrum of proteoglycans that occur in any particular type of extracellular matrix may be distinct. However, it seems that all extracellular matrices contain proteoglycans. Proteoglycans vary greatly in form and function. The small leucine-rich proteoglycan, decorin, is abundant in dense connective tissues where it associates with, and can regulate the formation of, interstitial collagen fibers (<xref ref-type="bibr" rid="bibr78-0022155412464638">Rada et al. 1993</xref>; <xref ref-type="bibr" rid="bibr81-0022155412464638">Reed and Iozzo 2002</xref>). Decorin bears a single dermatan or chondroitin sulfate chain. There is a family of related proteoglycans of the small leucine-rich type (<xref ref-type="table" rid="table1-0022155412464638">Table 1</xref>). At the opposite extreme, aggrecan is most abundant in cartilage and can be substituted with around 100 chains (<xref ref-type="bibr" rid="bibr6-0022155412464638">Aspberg 2012</xref>). Cartilage also contains type IX collagen that can possess a single chondroitin sulfate chain (<xref ref-type="bibr" rid="bibr13-0022155412464638">Brewton et al. 1991</xref>). Basement membranes contain several proteoglycans, three of which usually are substituted with heparan sulfate. They are perlecan, type XVIII collagen, and agrin. In terms of sequence and structure, the core proteins of these proteoglycans are completely unrelated. Nevertheless, basement membrane heparan sulfate may be an important determinant of, for example, growth factor sequestration, protection from proteases, and presentation in the correct configuration to cognate receptors (<xref ref-type="bibr" rid="bibr88-0022155412464638">Saksela et al. 1988</xref>; <xref ref-type="bibr" rid="bibr36-0022155412464638">Friedl et al. 1997</xref>; <xref ref-type="bibr" rid="bibr47-0022155412464638">Iozzo et al. 2009</xref>). Perlecan is not basement membrane restricted but occurs in several extracellular matrices, including cartilage.</p>
<p>On all but erythrocytes, one or more cell surface proteoglycans are present. Most are transmembrane, such as the HA receptor CD44 and the syndecans, but others, notably the six mammalian glypicans, are anchored by a glycosylphosphatidylinositol moiety to the outer membrane leaflet. It is common that glypican and syndecans coexist on cell surfaces, although each may be enriched in different compartments. It is possible that glypicans, by virtue of their anchor, localize to raft structures. In polarizing epithelia (<xref ref-type="bibr" rid="bibr30-0022155412464638">Dick et al. 2012</xref>), it is known that glypicans can concentrate in the apical membrane domain (<xref ref-type="bibr" rid="bibr40-0022155412464638">Gallet et al. 2008</xref>). Both the syndecans (<xref ref-type="bibr" rid="bibr33-0022155412464638">Eriksson and Spillman 2012</xref>) and glypicans have heparan sulfate GAGs predominantly, although syndecans-1 and -3 may also have chondroitin or dermatan sulfate in addition. The reason that these two proteoglycans may be hybrids is not entirely clear. Some cell surface proteoglycans may not be glycanated all the time. CD44, for example, is often not glycanated on leukocytes but in epithelia may bear heparan sulfate chains (<xref ref-type="bibr" rid="bibr14-0022155412464638">Brown et al. 1991</xref>). Frequently, in fibroblasts, it is substituted with a chondroitin or dermatan sulfate chain (<xref ref-type="bibr" rid="bibr61-0022155412464638">Malmström et al. 2012</xref>). This receptor is known for its highly complex alternate splicing at the mRNA level, and it is a particular splice variant that carries the sequence that includes the heparan sulfate acceptor site. Other cell surface proteoglycans such as neuropilin-1, a receptor for vascular endothelial growth factor (VEGF) and semaphorins, and betaglycan, a type III transforming growth factor (TGF)–β receptor, may on some occasions possess a heparan sulfate chain but on other occasions a chondroitin sulfate chain. It is known that the properties of neuropilin-1 may change as a result of this alternate glycanation (<xref ref-type="bibr" rid="bibr93-0022155412464638">Shintani et al. 2006</xref>). The transmembrane signaling proteoglycans have been reviewed in depth recently (<xref ref-type="bibr" rid="bibr24-0022155412464638">Couchman 2010</xref>). Many link indirectly to the actin cytoskeleton and also to submembranous protein networks represented by PDZ domain proteins (<xref ref-type="bibr" rid="bibr98-0022155412464638">Subbaiah et al. 2011</xref>).</p>
<p>It has been known for some time that mucosal and connective tissue mast cells contain granules with the proteoglycan serglycin (<xref ref-type="bibr" rid="bibr86-0022155412464638">Rönnberg et al. 2012</xref>). This proteoglycan gets its name from the serine-glycine rich motif that dominates its sequence. The serine residues are sites for heparin or chondroitin sulfate substitution. Commercial heparin for a long time has been prepared from gut that is rich in mucosal mast cells. Serglycin is, however, not restricted to mast cells but is found more widely, including in vascular endothelial cells, where it may regulate secretion of the chemokine GROα/CXCL1 (<xref ref-type="bibr" rid="bibr63-0022155412464638">Meen et al. 2011</xref>).</p>
<p>A number of proteoglycans, including syndecans and glypicans, have been reported from nuclear locations. For many years, the existence of nuclear proteoglycans was controversial, but reports are increasing, based mainly on immunocytochemistry. It has yet to be ascertained why this occurs and what function these highly anionic molecules may have in the nucleus (<xref ref-type="bibr" rid="bibr84-0022155412464638">Richardson et al. 2001</xref>; <xref ref-type="bibr" rid="bibr19-0022155412464638">Chen and Sanderson 2009</xref>). It is also not clear if whole proteoglycans are transported to nuclei or whether there is partial cleavage to liberate specific domains, presumably including some of the GAGs, which are then translocated. Certainly, many proteoglycans are sensitive to proteolytic cleavage. Syndecans in particular are highly susceptible to matrix metalloproteinases and other proteinases (<xref ref-type="bibr" rid="bibr62-0022155412464638">Manon-Jensen et al. 2010</xref>), and this may be an important part of their physiology with relevance to tissue repair and disease. Glypicans can be released from the cell surface by the GPI-phospholipase Notum (<xref ref-type="bibr" rid="bibr102-0022155412464638">Traister et al. 2008</xref>). In turn, this can lead to suppression of signaling through Wnts, for example.</p>
<p>Many proteoglycans are turned over and degraded through well-studied lysosomal pathways. Indeed, some important and devastating diseases in humans are known that arise from the lack of a specific enzyme in GAG hydrolysis. These rare genetic storage diseases are the subject of much current research with some new potential therapeutic approaches being considered (<xref ref-type="bibr" rid="bibr68-0022155412464638">Muenzer 2011</xref>; <xref ref-type="bibr" rid="bibr105-0022155412464638">Valayannopoulos and Wijburg 2011</xref>). In addition, HA has been described as a more general cytoplasmic component (<xref ref-type="bibr" rid="bibr43-0022155412464638">Hascall et al. 2004</xref>). The pathways that lead to this localization of HA are incompletely understood, and more recent research suggests that this accumulation may be a consequence of disturbed glucose metabolism (<xref ref-type="bibr" rid="bibr108-0022155412464638">Wang A and Hascall 2009</xref>; <xref ref-type="bibr" rid="bibr109-0022155412464638">Wang A et al. 2011</xref>).</p>
</sec>
<sec id="section4-0022155412464638">
<title>Proteoglycan Functions in Development, Tissue Architecture, and Disease</title>
<sec id="section5-0022155412464638">
<title>Knockouts of Genes Involved in Heparan Sulfate Synthesis and Observations on Stem Cells</title>
<p>A very large number of potent growth factors, morphogens, and cytokines have heparin-binding and heparan sulfate-binding properties. Therefore, it is not surprising that there is an extensive literature detailing many roles for heparan sulfate proteoglycans (HSPGs) in invertebrate and vertebrate development. As might be expected, there are some remarkably conserved roles for these proteoglycans. Moreover, genetic ablation of EXT1 or EXT2, which encode the components of a heterodimeric protein complex that is the major heparosan polymerase, leads to embryonic lethality. This is true of the mouse, and the equivalent experiments in <italic>Drosophila</italic> yield the same results, where, remarkably, human <italic>EXT1</italic> can rescue flies where the equivalent gene, <italic>tout velu</italic>, is deleted (<xref ref-type="bibr" rid="bibr27-0022155412464638">Dasgupta et al. 2007</xref>). Therefore, heparan sulfate is essential for multicellular life. A key property of heparan sulfate on the cell surface is that it can concentrate ligands for signaling through high-affinity receptors. A well-studied example is fibroblast growth factor (FGF; <xref ref-type="bibr" rid="bibr80-0022155412464638">Rapraeger et al. 1991</xref>). Many members of this large family bind heparan sulfate, and crystallographic studies reveal how the FGF/HS complex interacts with the FGF receptor (FGFR) kinases (<xref ref-type="bibr" rid="bibr74-0022155412464638">Pellegrini et al. 2000</xref>; <xref ref-type="bibr" rid="bibr92-0022155412464638">Schlessinger et al. 2000</xref>). Heparan sulfate can also control morphogen gradients (<xref ref-type="bibr" rid="bibr71-0022155412464638">Nahmad and Lander 2011</xref>) necessary for tissue differentiation events. Examples include wingless (Wnt in vertebrates) and hedgehog.</p>
<p>Much recent attention has been focused on embryonic stem cells and their potential for the treatment of a range of diseases. Stem cells are relatively rich in proteoglycans, and heparan sulfate has been shown to be essential for differentiation (<xref ref-type="bibr" rid="bibr95-0022155412464638">Smith et al. 2011</xref>; <xref ref-type="bibr" rid="bibr99-0022155412464638">Tamm et al. 2012</xref>). Embryonic stem cells derived from Ext1<sup>–/–</sup> mice, for example, are incapable of differentiation but can be rescued by exogenous heparin. These experiments underline the essential nature of heparan sulfate for mammalian development, probably because essential growth and differentiation factors require GAG interactions at the cell surface. This area is reviewed by <xref ref-type="bibr" rid="bibr99-0022155412464638">Tamm et al. (2012)</xref>. However, although heparan sulfate may be essential, no single knockout of a syndecan or glypican is embryonic lethal in the mouse, suggesting that in the embryonic stem cell context, there is redundancy among the core proteins that bear heparan sulfate.</p>
<p>Specific deletions of transferases that are involved in heparan sulfate synthesis have varying results. Deletion of NDST1 in the mouse is embryonic lethal (<xref ref-type="bibr" rid="bibr85-0022155412464638">Ringvall et al. 2000</xref>). This is perhaps unsurprising because <italic>N</italic>-sulfation is an early event in HS synthesis, so that a failure in this step leads to a global undersulfation of the GAG. However, deletion of the more selectively expressed NDST2 leads to defective mast cells, since heparin synthesis is compromised, but is not embryonic lethal (<xref ref-type="bibr" rid="bibr35-0022155412464638">Forsberg et al. 1999</xref>). Deletions of the 5′ epimerase or 2-<italic>O</italic>-sulfotransferase have similar outcomes, most notably renal agenesis, which leads to perinatal lethality (<xref ref-type="bibr" rid="bibr15-0022155412464638">Bullock et al. 1998</xref>; <xref ref-type="bibr" rid="bibr59-0022155412464638">Li et al. 2003</xref>). A later step in the synthesis of HS is 6-<italic>O</italic>-sulfation. However, the binding of many growth factors depends on this modification. As a result, 6OST1 deletion is also embryonic lethal in the mouse and in <italic>Drosophila</italic> (<xref ref-type="bibr" rid="bibr42-0022155412464638">Habuchi and Kimata 2010</xref>).</p>
</sec>
</sec>
<sec id="section6-0022155412464638">
<title>Proteoglycan Core Protein Genes—Knockouts and Genetic Diseases of Man</title>
<p>In contrast to ablation of enzymes involved in heparan sulfate synthesis, knockout of single syndecan core protein genes in the mouse has mild outcomes. Loss of syndecan-1, -3, or -4 all leads to phenotypes, but mice survive in every case and are fertile. For example, syndecan-1 and -4 mice have slowed tissue repair in injury models (<xref ref-type="bibr" rid="bibr9-0022155412464638">Bernfield et al. 1999</xref>; <xref ref-type="bibr" rid="bibr32-0022155412464638">Echtermeyer et al. 2001</xref>), whereas syndecan-3 null mice have neural defects that are quite mild (<xref ref-type="bibr" rid="bibr45-0022155412464638">Hienola et al. 2006</xref>). Syndecan-2 null mice have not been reported. This leads to the obvious conclusion that there is redundancy among the syndecans. Despite this, syndecans have specific signaling functions that do not overlap. Syndecan-4, for example, binds inositol phospholipid and protein kinase Cα, which then becomes activated and signals downstream to the actin cytoskeleton (<xref ref-type="bibr" rid="bibr22-0022155412464638">Couchman 2003</xref>, <xref ref-type="bibr" rid="bibr24-0022155412464638">2010</xref>). It seems likely that a common function of syndecans has yet to be elucidated that might explain the apparent redundancy that genetic experiments suggest. In invertebrates, there is a single syndecan gene, and evidence from <italic>C. elegans</italic> suggests that it has a role in migration of specific neurons through development (<xref ref-type="bibr" rid="bibr82-0022155412464638">Rhiner et al. 2005</xref>). As yet, however, the biochemical basis for its action is not understood.</p>
<p>There are six mammalian glypicans, and a rare human disease, Simpson-Golabi-Behmel syndrome, is associated with loss of function in glypican-3. This causes overgrowth, both in human patients and in the mouse knockout (<xref ref-type="bibr" rid="bibr34-0022155412464638">Filmus and Capurro 2008</xref>). Patients are also tumor prone and are particularly at risk of Wilms tumors. Research now suggests that glypican-3 has a role in inhibiting Hedgehog signaling through competition with its receptor, patched (<xref ref-type="bibr" rid="bibr17-0022155412464638">Capurro et al. 2008</xref>). More recently, there has been much interest in the connection between high levels of glypican-3 expression and the development of hepatocellular carcinoma (<xref ref-type="bibr" rid="bibr2-0022155412464638">Allegretta and Filmus 2011</xref>). This proteoglycan is now a target for cancer therapy. Human mutations in glypican-6 that are functionally null have been characterized in autosomal recessive omodysplasia, with pronounced limb shortening and craniofacial dysmorphism (<xref ref-type="bibr" rid="bibr16-0022155412464638">Campos-Xavier et al. 2009</xref>). A genome-wide association study, on the other hand, shows that acquired nephrotic syndrome can be associated with specific single-nucleotide polymorphisms (SNPs) in the glypican-5 gene (<xref ref-type="bibr" rid="bibr73-0022155412464638">Okamoto et al. 2011</xref>). In these cases, the suspicion is once again that there are defects in heparin-binding growth factor metabolism, for example, of the FGF family.</p>
<p>In contrast to syndecans, deletion of the perlecan gene, which encodes a major basement membrane HSPG, has catastrophic effects. In the mouse, around 40% mice die at around day 10 of embryonic development, with the remainder exhibiting profound defects, not in basement membranes as might have been predicted but in cartilage and cranial development. Perlecan is, therefore, essential for skeletal development. In a similar vein, patients with dyssegmental dysplasia of the Silverman-Handmaker type show gross skeletal malformations. They have functional null mutations in the perlecan gene. Less severe phenotypes are shown by patients with Schwartz-Jampel syndrome, where truncated forms of perlecan are expressed (<xref ref-type="bibr" rid="bibr4-0022155412464638">Arikawa-Hirasawa et al. 2001</xref>, <xref ref-type="bibr" rid="bibr3-0022155412464638">2002</xref>). The disease is marked by myotonic myopathy and chondrodysplasia. Along with structural roles, it may be that the heparan sulfate chains of perlecan have a role in binding skeletal growth factors and morphogens such as FGF18 and Indian Hedgehog (<xref ref-type="bibr" rid="bibr55-0022155412464638">Koziel et al. 2004</xref>; <xref ref-type="bibr" rid="bibr20-0022155412464638">Chuang et al. 2010</xref>). The lecticans get their name from a C-terminal globular domain that has lectin-like properties (<xref ref-type="bibr" rid="bibr6-0022155412464638">Aspberg 2012</xref>). A recent report from <xref ref-type="bibr" rid="bibr97-0022155412464638">Stattin et al. (2010)</xref> reveals that mutations in this domain of the large chondroitin sulfate proteoglycan (CSPG) aggrecan, seen in dominant familial osteochondritis dissecans, can have structural effects on the cartilage, with loss of extracellular matrix from the joint surface.</p>
</sec>
<sec id="section7-0022155412464638">
<title>Proteoglycans and Acquired Diseases</title>
<p>Given that proteoglycans occur in every tissue and on or in many varied cell types, it is not surprising that some receive attention through their potential roles in pathogenesis of acquired diseases. Moreover, GAGs can bind many potent mitogens that are thought to be relevant to proliferative diseases such as cancer. Many studies have been directed, for example, into the roles of syndecans in tumor progression. Syndecan-1 has been the focus of a majority of this work (<xref ref-type="bibr" rid="bibr101-0022155412464638">Teng et al. 2012</xref>), and in some cases, such as breast cancer, its expression, particularly where it is present not only in epithelial tissue but also in stroma, is correlated with poor prognosis (<xref ref-type="bibr" rid="bibr58-0022155412464638">Lendorf et al. 2011</xref>; <xref ref-type="bibr" rid="bibr113-0022155412464638">Yoneda et al. 2012</xref>). Much work also strongly suggests that the synthesis of syndecan-1 in myeloma is congruent with disease progression (<xref ref-type="bibr" rid="bibr50-0022155412464638">Khotskaya et al. 2009</xref>), to the extent that a current research focus is whether inhibition of syndecan-1 expression may lead to a novel therapeutic approach to this devastating disease.</p>
<p>Heparan sulfate-modifying enzymes are also under scrutiny with respect to tumor progression. In the human genome, there is a single heparanase that can cleave heparan sulfate chains into oligosaccharides that retain considerable biological activity (<xref ref-type="bibr" rid="bibr39-0022155412464638">Fux et al. 2009</xref>). This can affect the distribution of heparin-binding ligands such as growth factors, with downstream influences on gene expression and motility. It is upregulated in a number of tumor types and is associated with poor prognosis in many cases (<xref ref-type="bibr" rid="bibr5-0022155412464638">Arvatz et al. 2011</xref>; <xref ref-type="bibr" rid="bibr89-0022155412464638">Sanderson and Iozzo 2012</xref>). In addition, there are two sulfatases that can edit heparan sulfate after it is synthesized, probably on the cell surface. These enzymes selectively remove sulfate from the 6-<italic>O</italic>-position on heparan sulfate but not chondroitin sulfate. Many potent polypeptides use 6-<italic>O</italic>-sulfates as part of their binding site(s) on heparan sulfate, so their removal can liberate the proteins and increase their bioavailability. In this regard, Sulf2, in particular, is thought to be important for the progression of non–small cell lung cancer, as well as pancreatic and hepatocellular carcinoma (<xref ref-type="bibr" rid="bibr87-0022155412464638">Rosen and Lemjabbar-Alaoui 2010</xref>).</p>
<p>Heparanase has also recently been shown to be essential for development of diabetic nephropathy in mice (<xref ref-type="bibr" rid="bibr41-0022155412464638">Gil et al. 2012</xref>). Diabetes is a fast-growing problem in the developed world, and proteoglycans have long been a focus of research into pathological changes to extracellular matrices in diabetic tissue. Organ failure in long-term diabetics is in part due to pathological changes in matrix composition, and those changes occurring in the diabetic kidney are reviewed elsewhere (<xref ref-type="bibr" rid="bibr54-0022155412464638">Kolset et al. 2012</xref>). Originally, it was thought that basement membrane thickening and loss of heparan sulfate were key to filtration defects and proteinuria, but as <xref ref-type="bibr" rid="bibr54-0022155412464638">Kolset et al. (2012)</xref> describe, the situation appears to be more complex and diabetic nephropathy may encompass multiple changes to glomerular and tubular proteoglycans.</p>
<p>Aggrecan is one of four members of the lectican family of CSPGs. It is abundant in cartilage, where is contributes to essential structural properties, such as the ability to resist compressive forces. In part, this is due to the high negative charge of the GAG chains that attract counter-ions and water. Therefore, the loss of aggrecan in arthritis is an important part of disease etiology. Metalloproteinases are the major suspects in aggrecan cleavage and loss, and recent work has focused on the ADAMTS group of proteinases (<xref ref-type="bibr" rid="bibr60-0022155412464638">Majumdar et al. 2007</xref>; <xref ref-type="bibr" rid="bibr96-0022155412464638">Stanton et al. 2011</xref>; <xref ref-type="bibr" rid="bibr103-0022155412464638">Troeberg and Nagase 2012</xref>).</p>
<p>Versican, a large chondroitin proteoglycan of the lectican family, is a major vascular wall component that can also be the target of ADAMTS proteinases. This has implications for pathological angiogenesis (<xref ref-type="bibr" rid="bibr38-0022155412464638">Fu et al. 2011</xref>). Versican, therefore, has structural roles. However, an emerging theme is that many such structural proteoglycans have, in addition, signaling roles, particularly with respect to the immune system. Versican has been identified as upregulated in many tumors, including, lung, gastric, ovarian, breast, and melanoma (<xref ref-type="bibr" rid="bibr52-0022155412464638">Kim S et al. 2009</xref>; <xref ref-type="bibr" rid="bibr83-0022155412464638">Ricciardelli et al. 2009</xref>; <xref ref-type="bibr" rid="bibr31-0022155412464638">Du et al. 2010</xref>; <xref ref-type="bibr" rid="bibr111-0022155412464638">Ween et al. 2011</xref>, <xref ref-type="bibr" rid="bibr44-0022155412464638">Hernández et al. 2011</xref>). In 2009, it was identified as a macrophage activator, through cell surface TLR2:TLR6 complexes that in turn induced TNF-α secretion by myeloid cells, with downstream promotion of lung cancer metastasis (<xref ref-type="bibr" rid="bibr52-0022155412464638">Kim S et al. 2009</xref>). Versican may act at other levels also. In common with other family members, versican core protein has N-terminal (G1) and C-terminal (G3) globular domains (discussed for aggrecan in <xref ref-type="bibr" rid="bibr6-0022155412464638">Aspberg 2012</xref>). These globular domains may interact with many extracellular matrix components, and G1 interactions with HA are a defining character of the lectican class. However, it has been reported that the versican G3 domain may interact, directly or indirectly, with the epidermal growth factor receptor (<xref ref-type="bibr" rid="bibr44-0022155412464638">Hernández et al. 2011</xref>). Such signaling may promote mammary tumor and melanoma progression, for example (<xref ref-type="bibr" rid="bibr31-0022155412464638">Du et al. 2010</xref>; <xref ref-type="bibr" rid="bibr44-0022155412464638">Hernández et al. 2011</xref>).</p>
<p>Whether the other two members of the lectican family, neurocan and brevican, have similar functions through their globular domains is not yet clear. However, these two hyaluronan-binding proteoglycans are believed to have important roles in the central nervous system. A recent genome-wide association study reported significant association of a SNP in the 3′ untranslated region of the neurocan gene with bipolar disorder (<xref ref-type="bibr" rid="bibr21-0022155412464638">Cichon et al. 2011</xref>). Brevican is a component of the perineuronal net and is believed to have roles in synaptic plasticity, glioma invasion, postlesion plasticity, and, perhaps, Alzheimer disease (<xref ref-type="bibr" rid="bibr37-0022155412464638">Frishknecht and Seidenbecher 2012</xref>).</p>
<p>Several members of the small leucine-rich family of proteoglycans (SLRPs) are known to have roles in regulating collagen fibrillogenesis. The decorin null mouse, for example, has abnormal interstitial collagen fibers in the dermis (<xref ref-type="bibr" rid="bibr26-0022155412464638">Danielson et al. 1997</xref>). These small proteoglycans have the ability to bind to distinct regions on the collagen and through this regulate the assembly of fibrils into fibers. However, quite independent of this activity, it is also known that decorin can bind and inhibit TGF-β (<xref ref-type="bibr" rid="bibr11-0022155412464638">Border et al. 1992</xref>). TGF-β has many roles, both in development but also in response to tissue injury. Of particular significance is that TGF-β has been implicated in the pathogenesis of fibrosis. Signaling from TGF-β receptors leads fairly directly to transcriptional regulation of, for example, type I collagen genes (<xref ref-type="bibr" rid="bibr75-0022155412464638">Penttinen et al. 1988</xref>; <xref ref-type="bibr" rid="bibr10-0022155412464638">Biernacka et al. 2011</xref>). Therefore, the decorin/TGF-β axis has received much interest from a clinical perspective. A recent review on decorin and liver fibrosis covers this aspect in depth (<xref ref-type="bibr" rid="bibr7-0022155412464638">Baghy et al. 2012</xref>). Recent work, summarized in this volume (<xref ref-type="bibr" rid="bibr72-0022155412464638">Nastase et al. 2012</xref>), points to yet another vital function for members of the SLRP family, notably biglycan and decorin, and that is regulation of the innate immune system (<xref ref-type="bibr" rid="bibr66-0022155412464638">Moreth et al. 2010</xref>; <xref ref-type="bibr" rid="bibr64-0022155412464638">Merline et al. 2011</xref>).</p>
<p>Hyaluronan is now also considered a regulator of immune function (<xref ref-type="bibr" rid="bibr49-0022155412464638">Jiang et al. 2011</xref>), interacting with toll-like receptors, as can biglycan. This GAG is a widespread extracellular matrix component, is particularly abundant in developing tissues, and may contribute to a more open, hydrated, extracellular matrix network that allows cell migration. It is also an essential component of cartilage, so that HA is present in extracellular matrices of widely differing physical properties. In the mammalian eye, hyaluronan is a major component of the vitreous as well as being present in the corneal epithelium, conjunctiva, tears, and trabecular meshwork. HA-related products are now in use and under development for conditions such as vitreous replacement, dry eye, and retinal surgery (<xref ref-type="bibr" rid="bibr79-0022155412464638">Rah 2011</xref>). In addition, since HA can promote cell migration, it is also now under investigation with respect to tumor progression (<xref ref-type="bibr" rid="bibr1-0022155412464638">Afratis et al. 2012</xref>), and in some cases, hyaluronan-rich matrices may impede drug delivery or access to cell surface receptors, for example, ErbB2 (<xref ref-type="bibr" rid="bibr48-0022155412464638">Jacobetz et al. 2012</xref>; <xref ref-type="bibr" rid="bibr107-0022155412464638">Váradi et al. 2012</xref>). It is has also been shown that expression of the HAS2 HA synthase is related to that of TIMPs, tissue inhibitors of matrix metalloproteinases (<xref ref-type="bibr" rid="bibr8-0022155412464638">Bernert et al. 2011</xref>). The discovery some years ago that HA could be a cytoplasmic component has triggered further work to understand its origins and functions (<xref ref-type="bibr" rid="bibr109-0022155412464638">Wang A et al. 2011</xref>). It now seems that it may be associated with hyperglycemia and autophagy (<xref ref-type="bibr" rid="bibr108-0022155412464638">Wang A and Hascall 2009</xref>). Connections to diabetes are therefore possible, and since HA consists of <italic>N</italic>-acetylglucosamine and glucuronic acid, it suggests that cells may respond to elevated glucose levels by elevating synthesis of this GAG, which requires little energy consumption (<xref ref-type="bibr" rid="bibr100-0022155412464638">Tammi et al. 2011</xref>).</p>
</sec>
<sec id="section8-0022155412464638">
<title>Conclusions</title>
<p>A select group of proteins can become proteoglycans through the addition of GAG chains. Although some of these can be assigned into families, such as the syndecans, glypicans, SLRPs, and lecticans, others are single examples (e.g., CD44 and perlecan). The array of proteoglycans is wider in vertebrates than in invertebrates, but nevertheless there are some remarkable examples of conserved function through evolution. These are most obvious for the syndecans and glypicans. The lecticans and SLRPs are vertebrate inventions and relate to the increased complexity and variety of extracellular matrices in vertebrates and their more sophisticated immune systems. Considered in their entirety, however, it is clear that proteoglycans perform important functions in many and varied aspects of development, tissue repair, and also some common and rare diseases in humans. Much remains to be learned regarding the regulation of GAG synthesis, physiological roles, and potential importance as targets for disease treatment. The reviews that follow address some of these key issues.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors acknowledge support from the Danish National Research Foundation, Lundbeck Fonden, Novo Nordisk Fonden, a pilot grant from the Mizutani Foundation, and the Department of Biomedical Sciences at the University of Copenhagen. The Nordic Proteoglycans Workshop was supported by The Alfred Benzon Foundation.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Afratis</surname><given-names>N</given-names></name>
<name><surname>Gialeli</surname><given-names>C</given-names></name>
<name><surname>Nikitovic</surname><given-names>D</given-names></name>
<name><surname>Tsegenidis</surname><given-names>T</given-names></name>
<name><surname>Karousou</surname><given-names>E</given-names></name>
<name><surname>Theocharis</surname><given-names>A</given-names></name>
<name><surname>Pavão</surname><given-names>MS</given-names></name>
<name><surname>Tzanakakis</surname><given-names>GN</given-names></name>
<name><surname>Karamanos</surname><given-names>NK</given-names></name>
</person-group>. <year>2012</year>. <article-title>Glycosaminoglycans: key players in cancer biology and treatment</article-title>. <source>FEBS J</source>. <volume>279</volume>:<fpage>1177</fpage>–<lpage>1197</lpage>.</citation>
</ref>
<ref id="bibr2-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allegretta</surname><given-names>M</given-names></name>
<name><surname>Filmus</surname><given-names>J</given-names></name>
</person-group>. <year>2011</year>. <article-title>Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma</article-title>. <source>Anticancer Agents Med Chem</source>. <volume>11</volume>:<fpage>543</fpage>–<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr3-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arikawa-Hirasawa</surname><given-names>E</given-names></name>
<name><surname>Le</surname><given-names>AH</given-names></name>
<name><surname>Nishino</surname><given-names>I</given-names></name>
<name><surname>Ho</surname><given-names>NC</given-names></name>
<name><surname>Francomano</surname><given-names>CA</given-names></name>
<name><surname>Govindraj</surname><given-names>P</given-names></name>
<name><surname>Hassell</surname><given-names>JR</given-names></name>
<name><surname>Devaney</surname><given-names>JM</given-names></name>
<name><surname>Spranger</surname><given-names>J</given-names></name>
<name><surname>Stevenson</surname><given-names>RE</given-names></name>
<etal/></person-group>. <year>2002</year>. <article-title>Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia</article-title>. <source>Am J Hum Genet</source>. <volume>70</volume>:<fpage>1368</fpage>–<lpage>1375</lpage>.</citation>
</ref>
<ref id="bibr4-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arikawa-Hirasawa</surname><given-names>E</given-names></name>
<name><surname>Wilcox</surname><given-names>WR</given-names></name>
<name><surname>Le</surname><given-names>AH</given-names></name>
<name><surname>Sliverman</surname><given-names>N</given-names></name>
<name><surname>Govindraj</surname><given-names>P</given-names></name>
<name><surname>Hassell</surname><given-names>JR</given-names></name>
<name><surname>Yamada</surname><given-names>Y</given-names></name>
</person-group>. <year>2001</year>. <article-title>Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene</article-title>. <source>Nat Genet</source> <volume>27</volume>:<fpage>431</fpage>–<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr5-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arvatz</surname><given-names>G</given-names></name>
<name><surname>Shafat</surname><given-names>I</given-names></name>
<name><surname>Levy-Adam</surname><given-names>F</given-names></name>
<name><surname>Ilan</surname><given-names>N</given-names></name>
<name><surname>Voldavsky</surname><given-names>I</given-names></name>
</person-group>. <year>2011</year>. <article-title>The heparanase system and tumor metastasis: is heparanase the seed and soil?</article-title> <source>Cancer Metastasis Rev</source>. <volume>30</volume>:<fpage>253</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr6-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aspberg</surname><given-names>A</given-names></name>
</person-group>. <year>2012</year>. <article-title>The different roles of aggrecan interaction domains</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>987</fpage>–<lpage>996</lpage>.</citation>
</ref>
<ref id="bibr7-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baghy</surname><given-names>K</given-names></name>
<name><surname>Iozzo</surname><given-names>RV</given-names></name>
<name><surname>Kovalszky</surname><given-names>I</given-names></name>
</person-group>. <year>2012</year>. <article-title>Decorin-TGFβ axis in hepatic fibrosis and cirrhosis</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>262</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr8-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bernert</surname><given-names>B</given-names></name>
<name><surname>Porsch</surname><given-names>H</given-names></name>
<name><surname>Heldin</surname><given-names>P</given-names></name>
</person-group>. <year>2011</year>. <article-title>Hyaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1)</article-title>. <source>J Biol Chem</source>. <volume>286</volume>:<fpage>42349</fpage>–<lpage>42359</lpage>.</citation>
</ref>
<ref id="bibr9-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bernfield</surname><given-names>M</given-names></name>
<name><surname>Götte</surname><given-names>M</given-names></name>
<name><surname>Park</surname><given-names>PW</given-names></name>
<name><surname>Reizes</surname><given-names>O</given-names></name>
<name><surname>Fitzgerald</surname><given-names>ML</given-names></name>
<name><surname>Lincecum</surname><given-names>J</given-names></name>
<name><surname>Zako</surname><given-names>M</given-names></name>
</person-group>. <year>1999</year>. <article-title>Functions of cell surface heparan sulfate proteoglycans</article-title>. <source>Ann Rev Biochem</source>. <volume>68</volume>:<fpage>729</fpage>–<lpage>777</lpage>.</citation>
</ref>
<ref id="bibr10-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Biernacka</surname><given-names>A</given-names></name>
<name><surname>Dobaczewski</surname><given-names>M</given-names></name>
<name><surname>Frangogiannis</surname><given-names>NG</given-names></name>
</person-group>. <year>2011</year>. <article-title>TGF-β signaling in fibrosis</article-title>. <source>Growth Factors</source>. <volume>29</volume>:<fpage>196</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr11-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Border</surname><given-names>WA</given-names></name>
<name><surname>Noble</surname><given-names>NA</given-names></name>
<name><surname>Yamamoto</surname><given-names>T</given-names></name>
<name><surname>Harper</surname><given-names>JR</given-names></name>
<name><surname>Yamaguchi</surname><given-names>Y</given-names></name>
<name><surname>Pierschbacher</surname><given-names>MD</given-names></name>
<name><surname>Ruoslahti</surname><given-names>E</given-names></name>
</person-group>. <year>1992</year>. <article-title>Natural inhibitor of transforming growth factor–beta protects against scarring in experimental kidney disease</article-title>. <source>Nature</source>. <volume>360</volume>:<fpage>361</fpage>–<lpage>364</lpage>.</citation>
</ref>
<ref id="bibr12-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bourgignon</surname><given-names>LY</given-names></name>
<name><surname>Gilad</surname><given-names>E</given-names></name>
<name><surname>Peyrollier</surname><given-names>K</given-names></name>
</person-group>. <year>2007</year>. <article-title>Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration</article-title>. <source>J Biol Chem</source>. <volume>282</volume>:<fpage>19426</fpage>–<lpage>19441</lpage>.</citation>
</ref>
<ref id="bibr13-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brewton</surname><given-names>RG</given-names></name>
<name><surname>Wright</surname><given-names>DW</given-names></name>
<name><surname>Mayne</surname><given-names>R</given-names></name>
</person-group>. <year>1991</year>. <article-title>Structural and functional comparison of type IX collagen-proteoglycan from chicken cartilage and vitreous humor</article-title>. <source>J Biol Chem</source>. <volume>266</volume>:<fpage>4752</fpage>–<lpage>4757</lpage>.</citation>
</ref>
<ref id="bibr14-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brown</surname><given-names>TA</given-names></name>
<name><surname>Bouchard</surname><given-names>T</given-names></name>
<name><surname>St John</surname><given-names>T</given-names></name>
<name><surname>Wayner</surname><given-names>E</given-names></name>
<name><surname>Carter</surname><given-names>WG</given-names></name>
</person-group>. <year>1991</year>. <article-title>Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons</article-title>. <source>J Cell Biol</source>. <volume>113</volume>:<fpage>207</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr15-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bullock</surname><given-names>SL</given-names></name>
<name><surname>Fletcher</surname><given-names>JM</given-names></name>
<name><surname>Beddington</surname><given-names>RS</given-names></name>
<name><surname>Wilson</surname><given-names>VA</given-names></name>
</person-group>. <year>1998</year>. <article-title>Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase</article-title>. <source>Genes Dev</source>. <volume>12</volume>:<fpage>1894</fpage>–<lpage>1906</lpage>.</citation>
</ref>
<ref id="bibr16-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campos-Xavier</surname><given-names>AB</given-names></name>
<name><surname>Martinet</surname><given-names>D</given-names></name>
<name><surname>Bateman</surname><given-names>J</given-names></name>
<name><surname>Belluoccio</surname><given-names>D</given-names></name>
<name><surname>Rowley</surname><given-names>L</given-names></name>
<name><surname>Tan</surname><given-names>TY</given-names></name>
<name><surname>Baxová</surname><given-names>A</given-names></name>
<name><surname>Gustavson</surname><given-names>KH</given-names></name>
<name><surname>Borochowitz</surname><given-names>ZU</given-names></name>
<name><surname>Innes</surname><given-names>AM</given-names></name>
<etal/></person-group>. <year>2009</year>. <article-title>Mutations in the heparan-sulfate proteoglycan glypican-6 (GPC6) impair endochondral ossification and cause recessive omodysplasia</article-title>. <source>Am J Hum Genet</source>. <volume>84</volume>:<fpage>760</fpage>–<lpage>770</lpage>.</citation>
</ref>
<ref id="bibr17-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Capurro</surname><given-names>MI</given-names></name>
<name><surname>Xu</surname><given-names>P</given-names></name>
<name><surname>Shi</surname><given-names>W</given-names></name>
<name><surname>Li</surname><given-names>F</given-names></name>
<name><surname>Jia</surname><given-names>A</given-names></name>
<name><surname>Filmus</surname><given-names>J</given-names></name>
</person-group>. <year>2008</year>. <article-title>Glypican-3 inhibits hedgehog signaling during development by competing with patched for hedgehog binding</article-title>. <source>Dev Cell</source>. <volume>14</volume>:<fpage>700</fpage>–<lpage>711</lpage>.</citation>
</ref>
<ref id="bibr18-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caterson</surname><given-names>B</given-names></name>
</person-group>. <year>2012</year>. <article-title>Fell-Muir lecture: chondroitin sulphate glycosaminoglycans: fun for some and confusion for others</article-title>. <source>Int J Exp Pathol</source>. <volume>93</volume>:<fpage>1</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr19-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>L</given-names></name>
<name><surname>Sanderson</surname><given-names>RD</given-names></name>
</person-group>. <year>2009</year>. <article-title>Heparanase regulates levels of syndecan-1 in the nucleus</article-title>. <source>PLoS One</source>. <volume>4</volume>:<fpage>e4947</fpage>.</citation>
</ref>
<ref id="bibr20-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chuang</surname><given-names>CY</given-names></name>
<name><surname>Lord</surname><given-names>MS</given-names></name>
<name><surname>Melrose</surname><given-names>J</given-names></name>
<name><surname>Rees</surname><given-names>MD</given-names></name>
<name><surname>Knox</surname><given-names>SM</given-names></name>
<name><surname>Freeman</surname><given-names>C</given-names></name>
<name><surname>Iozzo</surname><given-names>RV</given-names></name>
<name><surname>Whitelock</surname><given-names>JM</given-names></name>
</person-group>. <year>2010</year>. <article-title>Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan</article-title>. <source>Biochemistry</source>. <volume>49</volume>:<fpage>5524</fpage>–<lpage>5532</lpage>.</citation>
</ref>
<ref id="bibr21-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cichon</surname><given-names>S</given-names></name>
<name><surname>Mühleisen</surname><given-names>TW</given-names></name>
<name><surname>Degenhardt</surname><given-names>FA</given-names></name>
<name><surname>Mattheisen</surname><given-names>M</given-names></name>
<name><surname>Miró</surname><given-names>X</given-names></name>
<name><surname>Strohmaier</surname><given-names>J</given-names></name>
<name><surname>Steffens</surname><given-names>M</given-names></name>
<name><surname>Meesters</surname><given-names>C</given-names></name>
<name><surname>Herms</surname><given-names>S</given-names></name>
<name><surname>Weingarten</surname><given-names>M</given-names></name>
<etal/></person-group>. <year>2011</year>. <article-title>Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder</article-title>. <source>Am J Hum Genet</source>. <volume>88</volume>:<fpage>372</fpage>–<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr22-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>2003</year>. <article-title>Syndecans: proteoglycan regulators of membrane microdomains?</article-title> <source>Nat Rev Mol Cell Biol</source>. <volume>4</volume>:<fpage>926</fpage>–<lpage>937</lpage>.</citation>
</ref>
<ref id="bibr23-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>2009</year>. <article-title>Commercial antibodies: the good bad and really ugly</article-title>. <source>J Histochem Cytochem</source>. <volume>57</volume>:<fpage>7</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr24-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>2010</year>. <article-title>Transmembrane signaling proteoglycans</article-title>. <source>Ann Rev Cell Dev Biol</source>. <volume>26</volume>:<fpage>89</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr25-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Couchman</surname><given-names>JR</given-names></name>
<name><surname>Caterson</surname><given-names>B</given-names></name>
<name><surname>Christner</surname><given-names>JE</given-names></name>
<name><surname>Baker</surname><given-names>JR</given-names></name>
</person-group>. <year>1984</year>. <article-title>Mapping by monoclonal antibody detection of glycosaminoglycans in connective tissues</article-title>. <source>Nature</source>. <volume>307</volume>:<fpage>650</fpage>–<lpage>652</lpage>.</citation>
</ref>
<ref id="bibr26-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Danielson</surname><given-names>KG</given-names></name>
<name><surname>Baribault</surname><given-names>H</given-names></name>
<name><surname>Holmes</surname><given-names>DF</given-names></name>
<name><surname>Graham</surname><given-names>H</given-names></name>
<name><surname>Kadler</surname><given-names>KE</given-names></name>
<name><surname>Iozzo</surname><given-names>RV</given-names></name>
</person-group>. <year>1997</year>. <article-title>Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility</article-title>. <source>J Cell Biol</source>. <volume>136</volume>:<fpage>729</fpage>–<lpage>743</lpage>.</citation>
</ref>
<ref id="bibr27-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dasgupta</surname><given-names>U</given-names></name>
<name><surname>Dixit</surname><given-names>BL</given-names></name>
<name><surname>Rusch</surname><given-names>M</given-names></name>
<name><surname>Selleck</surname><given-names>S</given-names></name>
<name><surname>The</surname><given-names>I</given-names></name>
</person-group>. <year>2007</year>. <article-title>Functional conservation of the human <italic>EXT1</italic> tumor suppressor gene and its <italic>Drosophila</italic> homolog <italic>tout velu</italic></article-title>. <source>Dev Genes Evol</source>. <volume>217</volume>:<fpage>555</fpage>–<lpage>561</lpage>.</citation>
</ref>
<ref id="bibr28-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>David</surname><given-names>G</given-names></name>
<name><surname>Bai</surname><given-names>XM</given-names></name>
<name><surname>van der Scheuren</surname><given-names>B</given-names></name>
<name><surname>Cassiman</surname><given-names>JJ</given-names></name>
<name><surname>van den Berghe</surname><given-names>H</given-names></name>
</person-group>. <year>1992</year>. <article-title>Developmental changes in heparan sulfate expression: in situ detection with mAbs</article-title>. <source>J Cell Biol</source>. <volume>119</volume>:<fpage>961</fpage>–<lpage>975</lpage>.</citation>
</ref>
<ref id="bibr29-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de la Motte</surname><given-names>CA</given-names></name>
<name><surname>Drazba</surname><given-names>JA</given-names></name>
</person-group>. <year>2011</year>. <article-title>Viewing hyaluronan: imaging contributes to imagining new roles for this amazing matrix polymer</article-title>. <source>J Histochem Cytochem</source>. <volume>59</volume>:<fpage>252</fpage>–<lpage>257</lpage>.</citation>
</ref>
<ref id="bibr30-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dick</surname><given-names>G</given-names></name>
<name><surname>Akslen-Hoel</surname><given-names>LK</given-names></name>
<name><surname>Grøndahl</surname><given-names>F</given-names></name>
<name><surname>Kjos</surname><given-names>I</given-names></name>
<name><surname>Prydz</surname><given-names>K</given-names></name>
</person-group>. <year>2012</year>. <article-title>Proteoglycans synthesis and Golgi organization in polarized epithelial cells</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>926</fpage>–<lpage>935</lpage>.</citation>
</ref>
<ref id="bibr31-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Du</surname><given-names>WW</given-names></name>
<name><surname>Yang</surname><given-names>BB</given-names></name>
<name><surname>Shatseva</surname><given-names>TA</given-names></name>
<name><surname>Yang</surname><given-names>BL</given-names></name>
<name><surname>Deng</surname><given-names>Z</given-names></name>
<name><surname>Shan</surname><given-names>SW</given-names></name>
<name><surname>Lee</surname><given-names>DY</given-names></name>
<name><surname>Seth</surname><given-names>A</given-names></name>
<name><surname>Yee</surname><given-names>AJ</given-names></name>
</person-group>. <year>2010</year>. <article-title>Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor</article-title>. <source>PLoS One</source>. <volume>5</volume>:<fpage>e13828</fpage>.</citation>
</ref>
<ref id="bibr32-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Echtermeyer</surname><given-names>F</given-names></name>
<name><surname>Streit</surname><given-names>M</given-names></name>
<name><surname>Wilcox-Adelman</surname><given-names>S</given-names></name>
<name><surname>Saoncella</surname><given-names>S</given-names></name>
<name><surname>Denhez</surname><given-names>F</given-names></name>
<name><surname>Detmar</surname><given-names>M</given-names></name>
<name><surname>Goetinck</surname><given-names>P</given-names></name>
</person-group>. <year>2001</year>. <article-title>Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4</article-title>. <source>J Clin Invest</source>. <volume>107</volume>:<fpage>R9</fpage>–<lpage>R14</lpage>.</citation>
</ref>
<ref id="bibr33-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eriksson</surname><given-names>AS</given-names></name>
<name><surname>Spillmann</surname><given-names>D</given-names></name>
</person-group>. <year>2012</year>. <article-title>The mutual impact of syndecan-1 and its glycosaminoglycan chains: a multivariate puzzle</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>936</fpage>–<lpage>942</lpage>.</citation>
</ref>
<ref id="bibr34-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filmus</surname><given-names>J</given-names></name>
<name><surname>Capurro</surname><given-names>M</given-names></name>
</person-group>. <year>2008</year>. <article-title>The role of glypican-3 in the regulation of body size and cancer</article-title>. <source>Cell Cycle</source>. <volume>7</volume>:<fpage>2787</fpage>–<lpage>2790</lpage>.</citation>
</ref>
<ref id="bibr35-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Forsberg</surname><given-names>E</given-names></name>
<name><surname>Pejler</surname><given-names>G</given-names></name>
<name><surname>Ringvall</surname><given-names>M</given-names></name>
<name><surname>Lunderius</surname><given-names>C</given-names></name>
<name><surname>Tomasini-Johansson</surname><given-names>B</given-names></name>
<name><surname>Kusche-Gullberg</surname><given-names>M</given-names></name>
<name><surname>Eriksson</surname><given-names>I</given-names></name>
<name><surname>Ledin</surname><given-names>J</given-names></name>
<name><surname>Hellman</surname><given-names>L</given-names></name>
<name><surname>Kjellén</surname><given-names>L</given-names></name>
</person-group>. <year>1999</year>. <article-title>Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme</article-title>. <source>Nature</source>. <volume>400</volume>:<fpage>773</fpage>–<lpage>776</lpage>.</citation>
</ref>
<ref id="bibr36-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Friedl</surname><given-names>A</given-names></name>
<name><surname>Chang</surname><given-names>Z</given-names></name>
<name><surname>Tierney</surname><given-names>A</given-names></name>
<name><surname>Rapraeger</surname><given-names>AC</given-names></name>
</person-group>. <year>1997</year>. <article-title>Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissues</article-title>. <source>Am J Pathol</source>. <volume>150</volume>:<fpage>1443</fpage>–<lpage>1455</lpage>.</citation>
</ref>
<ref id="bibr37-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frischknecht</surname><given-names>R</given-names></name>
<name><surname>Seidenbecher</surname><given-names>CI</given-names></name>
</person-group>. <year>2012</year>. <article-title>Brevican: a key proteoglycan in the perisynaptic extracellular matrix of the brain</article-title>. <source>Int J Biochem Cell Biol</source>. <volume>44</volume>:<fpage>1051</fpage>–<lpage>1054</lpage>.</citation>
</ref>
<ref id="bibr38-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fu</surname><given-names>Y</given-names></name>
<name><surname>Nagy</surname><given-names>JA</given-names></name>
<name><surname>Brown</surname><given-names>LF</given-names></name>
<name><surname>Shih</surname><given-names>S-C</given-names></name>
<name><surname>Johnson</surname><given-names>PY</given-names></name>
<name><surname>Chan</surname><given-names>CK</given-names></name>
<name><surname>Dvorak</surname><given-names>HF</given-names></name>
<name><surname>Wight</surname><given-names>TN</given-names></name>
</person-group>. <year>2011</year>. <article-title>Proteolytic cleavage of versican and involvement of ADAMTS-1 in VEGF-A/VPF induced pathological angiogenesis</article-title>. <source>J Histochem Cytochem</source>. <volume>59</volume>:<fpage>463</fpage>–<lpage>473</lpage>.</citation>
</ref>
<ref id="bibr39-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fux</surname><given-names>L</given-names></name>
<name><surname>Ilan</surname><given-names>N</given-names></name>
<name><surname>Sanderson</surname><given-names>RD</given-names></name>
<name><surname>Voldavsky</surname><given-names>I</given-names></name>
</person-group>. <year>2009</year>. <article-title>Heparanase: busy at the cell surface</article-title>. <source>Trends Biochem Sci</source>. <volume>34</volume>:<fpage>511</fpage>–<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr40-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gallet</surname><given-names>A</given-names></name>
<name><surname>Staccini-Lavenant</surname><given-names>L</given-names></name>
<name><surname>Thérond</surname><given-names>PP</given-names></name>
</person-group>. <year>2008</year>. <article-title>Cellular trafficking of the glypican Dally-like is required for full-strength hedgehog signaling and wingless transcytosis</article-title>. <source>Dev Cell</source>. <volume>14</volume>:<fpage>712</fpage>–<lpage>725</lpage>.</citation>
</ref>
<ref id="bibr41-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gil</surname><given-names>N</given-names></name>
<name><surname>Goldberg</surname><given-names>R</given-names></name>
<name><surname>Newman</surname><given-names>T</given-names></name>
<name><surname>Garsen</surname><given-names>M</given-names></name>
<name><surname>Zcharia</surname><given-names>E</given-names></name>
<name><surname>Rubinstein</surname><given-names>AM</given-names></name>
<name><surname>van Kuppevelt</surname><given-names>T</given-names></name>
<name><surname>Meirovitz</surname><given-names>A</given-names></name>
<name><surname>Pisano</surname><given-names>C</given-names></name>
<name><surname>Li</surname><given-names>JP</given-names></name>
<etal/></person-group>. <year>2012</year>. <article-title>Heparanase is essential fort he development of diabetic nephropathy</article-title>. <source>Diabetes</source>. <volume>61</volume>:<fpage>208</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr42-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Habuchi</surname><given-names>H</given-names></name>
<name><surname>Kimata</surname><given-names>K</given-names></name>
</person-group>. <year>2010</year>. <article-title>Mice deficient in heparan sulfate 6-O-sulfotransferase 1</article-title>. <source>Prog Mol Biol Trans Sci</source>. <volume>93</volume>:<fpage>79</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr43-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hascall</surname><given-names>VC</given-names></name>
<name><surname>Majors</surname><given-names>AK</given-names></name>
<name><surname>de</surname><given-names>la</given-names></name>
<name><surname>Motte</surname><given-names>CA</given-names></name>
<name><surname>Evanko</surname><given-names>SP</given-names></name>
<name><surname>Wang</surname><given-names>A</given-names></name>
<name><surname>Drazba</surname><given-names>JA</given-names></name>
<name><surname>Strong</surname><given-names>SA</given-names></name>
<name><surname>Wight</surname><given-names>TN</given-names></name>
</person-group>. <year>2004</year>. <article-title>Intracellular hyaluronan: a new frontier for inflammation?</article-title> <source>Biochim Biophys Acta</source>. <volume>1673</volume>:<fpage>3</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr44-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hernández</surname><given-names>D</given-names></name>
<name><surname>Miguel-Serra</surname><given-names>L</given-names></name>
<name><surname>Docampo</surname><given-names>MJ</given-names></name>
<name><surname>Marco-Ramell</surname><given-names>A</given-names></name>
<name><surname>Cabrera</surname><given-names>J</given-names></name>
<name><surname>Fabra</surname><given-names>A</given-names></name>
<name><surname>Bassols</surname><given-names>A</given-names></name>
</person-group>. <year>2011</year>. <article-title>V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling</article-title>. <source>J Biol Chem</source>. <volume>286</volume>:<fpage>1475</fpage>–<lpage>1485</lpage>.</citation>
</ref>
<ref id="bibr45-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hienola</surname><given-names>A</given-names></name>
<name><surname>Tumova</surname><given-names>S</given-names></name>
<name><surname>Kulesskiy</surname><given-names>E</given-names></name>
<name><surname>Rauvala</surname><given-names>H</given-names></name>
</person-group>. <year>2006</year>. <article-title>N-syndecan deficiency impairs neural migration in brain</article-title>. <source>J Cell Biol</source>. <volume>174</volume>:<fpage>569</fpage>–<lpage>580</lpage>.</citation>
</ref>
<ref id="bibr46-0022155412464638">
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Iozzo</surname><given-names>RV</given-names></name>
</person-group>. (ed). <year>2001</year>. <source>Proteoglycan protocols</source>. <publisher-loc>Totowa, NJ</publisher-loc>: <publisher-name>Humana</publisher-name>.</citation>
</ref>
<ref id="bibr47-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iozzo</surname><given-names>RV</given-names></name>
<name><surname>Zoeller</surname><given-names>JJ</given-names></name>
<name><surname>Nystrom</surname><given-names>A</given-names></name>
</person-group>. <year>2009</year>. <article-title>Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis</article-title>. <source>Mol Cells</source>. <volume>27</volume>:<fpage>503</fpage>–<lpage>513</lpage>.</citation>
</ref>
<ref id="bibr48-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jacobetz</surname><given-names>MA</given-names></name>
<name><surname>Chan</surname><given-names>DS</given-names></name>
<name><surname>Neesse</surname><given-names>A</given-names></name>
<name><surname>Bapiro</surname><given-names>TE</given-names></name>
<name><surname>Cook</surname><given-names>N</given-names></name>
<name><surname>Frese</surname><given-names>KK</given-names></name>
<name><surname>Feig</surname><given-names>C</given-names></name>
<name><surname>Nakagawa</surname><given-names>T</given-names></name>
<name><surname>Caldwell</surname><given-names>ME</given-names></name>
<name><surname>Zecchini</surname><given-names>HI</given-names></name>
<etal/></person-group>. <year>2012</year>. <article-title>Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer</article-title>. <source>Gut</source>. In press.</citation>
</ref>
<ref id="bibr49-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>D</given-names></name>
<name><surname>Liang</surname><given-names>J</given-names></name>
<name><surname>Noble</surname><given-names>PW</given-names></name>
</person-group>. <year>2011</year>. <article-title>Hyaluronan as an immune regulator in human diseases</article-title>. <source>Physiol Rev</source>. <volume>91</volume>:<fpage>221</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr50-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khotskaya</surname><given-names>YB</given-names></name>
<name><surname>Dai</surname><given-names>Y</given-names></name>
<name><surname>Ritchie</surname><given-names>JP</given-names></name>
<name><surname>MacLeod</surname><given-names>V</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>Zinn</surname><given-names>K</given-names></name>
<name><surname>Sanderson</surname><given-names>RD</given-names></name>
</person-group>. <year>2009</year>. <article-title>Syndecan-1 is required for robust growth, vascularisation and metastasis of myeloma tumors in vivo</article-title>. <source>J Biol Chem</source>. <volume>284</volume>:<fpage>26085</fpage>–<lpage>26095</lpage>.</citation>
</ref>
<ref id="bibr51-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>JS</given-names></name>
<name><surname>Werth</surname><given-names>VP</given-names></name>
</person-group>. <year>2011</year>. <article-title>Identification of specific chondroitin sulfate species in cutaneous autoimmune disease</article-title>. <source>J Histochem Cytochem</source>. <volume>59</volume>:<fpage>780</fpage>–<lpage>790</lpage>.</citation>
</ref>
<ref id="bibr52-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S</given-names></name>
<name><surname>Takahashi</surname><given-names>H</given-names></name>
<name><surname>Lin</surname><given-names>WW</given-names></name>
<name><surname>Descargues</surname><given-names>P</given-names></name>
<name><surname>Grivennikov</surname><given-names>S</given-names></name>
<name><surname>Kim</surname><given-names>Y</given-names></name>
<name><surname>Luo</surname><given-names>JL</given-names></name>
<name><surname>Karin</surname><given-names>M</given-names></name>
</person-group>. <year>2009</year>. <article-title>Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis</article-title>. <source>Nature</source>. <volume>457</volume>:<fpage>102</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr53-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>Y</given-names></name>
<name><surname>Lee</surname><given-names>YS</given-names></name>
<name><surname>Choe</surname><given-names>J</given-names></name>
<name><surname>Lee</surname><given-names>H</given-names></name>
<name><surname>Kim</surname><given-names>YM</given-names></name>
<name><surname>Jeoung</surname><given-names>D</given-names></name>
</person-group>. <year>2008</year>. <article-title>CD44–hyaluronic acid–promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase and MMP-2</article-title>. <source>J Biol Chem</source>. <volume>283</volume>:<fpage>22513</fpage>–<lpage>22528</lpage>.</citation>
</ref>
<ref id="bibr54-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kolset</surname><given-names>SO</given-names></name>
<name><surname>Reinholt</surname><given-names>FP</given-names></name>
<name><surname>Jenssen</surname><given-names>T</given-names></name>
</person-group>. <year>2012</year>. <article-title>Diabetic nephropathy and extracellular matrix</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>975</fpage>–<lpage>986</lpage>.</citation>
</ref>
<ref id="bibr55-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koziel</surname><given-names>L</given-names></name>
<name><surname>Kunath</surname><given-names>M</given-names></name>
<name><surname>Kelly</surname><given-names>OG</given-names></name>
<name><surname>Vortkamp</surname><given-names>A</given-names></name>
</person-group>. <year>2004</year>. <article-title>Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification</article-title>. <source>Dev Cell</source>. <volume>6</volume>:<fpage>801</fpage>–<lpage>813</lpage>.</citation>
</ref>
<ref id="bibr56-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kreuger</surname><given-names>J</given-names></name>
<name><surname>Kjellén</surname><given-names>L</given-names></name>
</person-group>. <year>2012</year>. <article-title>Heparan sulfate biosynthesis: regulation and variability</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>898</fpage>–<lpage>907</lpage>.</citation>
</ref>
<ref id="bibr57-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemire</surname><given-names>JM</given-names></name>
<name><surname>Braun</surname><given-names>KR</given-names></name>
<name><surname>Maurel</surname><given-names>P</given-names></name>
<name><surname>Kaplan</surname><given-names>ED</given-names></name>
<name><surname>Schwartz</surname><given-names>SM</given-names></name>
<name><surname>Wight</surname><given-names>TN</given-names></name>
</person-group>. <year>1999</year>. <article-title>Versican/PG-M isoforms in vascular smooth muscle cells</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <volume>19</volume>:<fpage>1630</fpage>–<lpage>1639</lpage>.</citation>
</ref>
<ref id="bibr58-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lendorf</surname><given-names>ME</given-names></name>
<name><surname>Manon-Jensen</surname><given-names>T</given-names></name>
<name><surname>Kronqvist</surname><given-names>P</given-names></name>
<name><surname>Multhaupt</surname><given-names>HAB</given-names></name>
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>2011</year>. <article-title>Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma</article-title>. <source>J Histochem Cytochem</source>. <volume>59</volume>:<fpage>615</fpage>–<lpage>629</lpage>.</citation>
</ref>
<ref id="bibr59-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>JP</given-names></name>
<name><surname>Gong</surname><given-names>F</given-names></name>
<name><surname>Hagner-McWhirter</surname><given-names>A</given-names></name>
<name><surname>Forsberg</surname><given-names>E</given-names></name>
<name><surname>Abrink</surname><given-names>M</given-names></name>
<name><surname>Kisilevsky</surname><given-names>R</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Lindahl</surname><given-names>U</given-names></name>
</person-group>. <year>2003</year>. <article-title>Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate lacking L-iduronic acid and in neonatal lethality</article-title>. <source>J Biol Chem</source>. <volume>278</volume>:<fpage>28363</fpage>–<lpage>28366</lpage>.</citation>
</ref>
<ref id="bibr60-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Majumdar</surname><given-names>MK</given-names></name>
<name><surname>Askew</surname><given-names>R</given-names></name>
<name><surname>Schelling</surname><given-names>S</given-names></name>
<name><surname>Stedman</surname><given-names>N</given-names></name>
<name><surname>Blanchet</surname><given-names>T</given-names></name>
<name><surname>Hopkins</surname><given-names>B</given-names></name>
<name><surname>Morris</surname><given-names>EA</given-names></name>
<name><surname>Glasson</surname><given-names>SS</given-names></name>
</person-group>. <year>2007</year>. <article-title>Double knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis</article-title>. <source>Arth Rheum</source>. <volume>56</volume>:<fpage>3670</fpage>–<lpage>3674</lpage>.</citation>
</ref>
<ref id="bibr61-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malmström</surname><given-names>A</given-names></name>
<name><surname>Bartolini</surname><given-names>B</given-names></name>
<name><surname>Thelin</surname><given-names>MA</given-names></name>
<name><surname>Pacheco</surname><given-names>B</given-names></name>
<name><surname>Maccarana</surname><given-names>M</given-names></name>
</person-group>. <year>2012</year>. <article-title>Iduronic acid in chondroitin/dermatan sulfate: biosynthesis and biological function</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>916</fpage>–<lpage>925</lpage>.</citation>
</ref>
<ref id="bibr62-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manon-Jensen</surname><given-names>T</given-names></name>
<name><surname>Itoh</surname><given-names>Y</given-names></name>
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>2010</year>. <article-title>Proteoglycans in health and disease: the multiple roles of syndecan shedding</article-title>. <source>FEBS J</source>. <volume>277</volume>:<fpage>3876</fpage>–<lpage>3889</lpage>.</citation>
</ref>
<ref id="bibr63-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meen</surname><given-names>AJ</given-names></name>
<name><surname>Øynebråten</surname><given-names>I</given-names></name>
<name><surname>Reine</surname><given-names>TM</given-names></name>
<name><surname>Duelli</surname><given-names>A</given-names></name>
<name><surname>Svennevig</surname><given-names>K</given-names></name>
<name><surname>Pejler</surname><given-names>G</given-names></name>
<name><surname>Jenssen</surname><given-names>T</given-names></name>
<name><surname>Kolset</surname><given-names>SO</given-names></name>
</person-group>. <year>2011</year>. <article-title>Serglycan is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemoskine GROα/CXCL1</article-title>. <source>J Biol Chem</source>. <volume>286</volume>:<fpage>2636</fpage>–<lpage>2647</lpage>.</citation>
</ref>
<ref id="bibr64-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Merline</surname><given-names>R</given-names></name>
<name><surname>Moreth</surname><given-names>K</given-names></name>
<name><surname>Beckmann</surname><given-names>J</given-names></name>
<name><surname>Nastase</surname><given-names>MV</given-names></name>
<name><surname>Zeng-Brouwers</surname><given-names>J</given-names></name>
<name><surname>Tralhão</surname><given-names>JG</given-names></name>
<name><surname>Lemarchand</surname><given-names>P</given-names></name>
<name><surname>Pfeilschifter</surname><given-names>J</given-names></name>
<name><surname>Schaefer</surname><given-names>RM</given-names></name>
<name><surname>Iozzo</surname><given-names>RV, et al</given-names></name>
<etal/></person-group>. <year>2011</year>. <article-title>Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and microRNA-21</article-title>. <source>Sci Signal</source>. <volume>4</volume>:<fpage>ra75</fpage>.</citation>
</ref>
<ref id="bibr65-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Misra</surname><given-names>S</given-names></name>
<name><surname>Obeid</surname><given-names>LM</given-names></name>
<name><surname>Hannun</surname><given-names>YA</given-names></name>
<name><surname>Minamisawa</surname><given-names>S</given-names></name>
<name><surname>Berger</surname><given-names>FG</given-names></name>
<name><surname>Markwald</surname><given-names>RR</given-names></name>
<name><surname>Toole</surname><given-names>BP</given-names></name>
<name><surname>Ghatak</surname><given-names>S</given-names></name>
</person-group>. <year>2008</year>. <article-title>Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells</article-title>. <source>J Biol Chem</source>. <volume>283</volume>:<fpage>14335</fpage>–<lpage>14344</lpage>.</citation>
</ref>
<ref id="bibr66-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moreth</surname><given-names>K</given-names></name>
<name><surname>Brodbeck</surname><given-names>R</given-names></name>
<name><surname>Babelova</surname><given-names>A</given-names></name>
<name><surname>Gretz</surname><given-names>N</given-names></name>
<name><surname>Spieker</surname><given-names>T</given-names></name>
<name><surname>Zeng-Brouwers</surname><given-names>J</given-names></name>
<name><surname>Pfeilschifter</surname><given-names>J</given-names></name>
<name><surname>Young</surname><given-names>MF</given-names></name>
<name><surname>Schaefer</surname><given-names>RM</given-names></name>
<name><surname>Schaefer</surname><given-names>L</given-names></name>
</person-group>. <year>2010</year>. <article-title>The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL-13 and aggravates murine lupus nephritis</article-title>. <source>J Clin Invest</source>. <volume>120</volume>:<fpage>4251</fpage>–<lpage>4272</lpage>.</citation>
</ref>
<ref id="bibr67-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>MR</given-names></name>
<name><surname>Humphries</surname><given-names>MJ</given-names></name>
<name><surname>Bass</surname><given-names>MD</given-names></name>
</person-group>. <year>2007</year>. <article-title>Synergistic control of cell adhesion by integrins and syndecans</article-title>. <source>Nat Rev Mol Cell Biol</source>. <volume>8</volume>:<fpage>957</fpage>–<lpage>969</lpage>.</citation>
</ref>
<ref id="bibr68-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muenzer</surname><given-names>J</given-names></name>
</person-group>. <year>2011</year>. <article-title>Overview of the mucopolysaccharidoses</article-title>. <source>Rheumatology (Oxford)</source>. <volume>50</volume>:<fpage>v4</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr69-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Multhaupt</surname><given-names>HAB</given-names></name>
<name><surname>Couchman</surname><given-names>JR</given-names></name>
</person-group>. <year>2012</year>. <article-title>Heparan sulfate biosynthesis: methods for investigation of the heparanosome</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>908</fpage>–<lpage>915</lpage>.</citation>
</ref>
<ref id="bibr70-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murakami</surname><given-names>M</given-names></name>
<name><surname>Simons</surname><given-names>M</given-names></name>
</person-group>. <year>2008</year>. <article-title>Fibroblast growth factor regulation of neovascularisation</article-title>. <source>Curr Opin Hematol</source>. <volume>15</volume>:<fpage>215</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr71-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nahmad</surname><given-names>M</given-names></name>
<name><surname>Lander</surname><given-names>AD</given-names></name>
</person-group>. <year>2011</year>. <article-title>Spatiotemporal mechanisms of morphogen gradient interpretation</article-title>. <source>Curr Opin Genet Dev</source>. <volume>21</volume>:<fpage>726</fpage>–<lpage>731</lpage>.</citation>
</ref>
<ref id="bibr72-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nastase</surname><given-names>MV</given-names></name>
<name><surname>Young</surname><given-names>MF</given-names></name>
<name><surname>Schaefer</surname><given-names>L</given-names></name>
</person-group>. <year>2012</year>. <article-title>Biglycan: a multivalent proteoglycan providing structure and signals</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>963</fpage>–<lpage>975</lpage>.</citation>
</ref>
<ref id="bibr73-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okamoto</surname><given-names>K</given-names></name>
<name><surname>Tokunaga</surname><given-names>K</given-names></name>
<name><surname>Doi</surname><given-names>K</given-names></name>
<name><surname>Fujita</surname><given-names>T</given-names></name>
<name><surname>Suzuki</surname><given-names>H</given-names></name>
<name><surname>Katoh</surname><given-names>T</given-names></name>
<name><surname>Watanabe</surname><given-names>T</given-names></name>
<name><surname>Nishida</surname><given-names>N</given-names></name>
<name><surname>Mabuchi</surname><given-names>A</given-names></name>
<name><surname>Takahashi</surname><given-names>A</given-names></name>
<etal/></person-group>. <year>2011</year>. <article-title>Common variation in GPC5 is associated with acquired nephritic syndrome</article-title>. <source>Nat Genet</source>. <volume>43</volume>:<fpage>459</fpage>–<lpage>463</lpage>.</citation>
</ref>
<ref id="bibr74-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pellegrini</surname><given-names>L</given-names></name>
<name><surname>Burke</surname><given-names>DF</given-names></name>
<name><surname>von Delft</surname><given-names>F</given-names></name>
<name><surname>Mulloy</surname><given-names>B</given-names></name>
<name><surname>Blundell</surname><given-names>TL</given-names></name>
</person-group>. <year>2000</year>. <article-title>Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin</article-title>. <source>Nature</source>. <volume>407</volume>:<fpage>1029</fpage>–<lpage>1034</lpage>.</citation>
</ref>
<ref id="bibr75-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Penttinen</surname><given-names>RP</given-names></name>
<name><surname>Kobayashi</surname><given-names>S</given-names></name>
<name><surname>Bornstein</surname><given-names>P</given-names></name>
</person-group>. <year>1988</year>. <article-title>Transforming growth factor beta increases mRNA for matrix proteins in the presence and absence of changes in mRNA stability</article-title>. <source>Proc Natl Acad Sci U S A</source>. <volume>85</volume>:<fpage>1105</fpage>–<lpage>1108</lpage>.</citation>
</ref>
<ref id="bibr76-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ponta</surname><given-names>H</given-names></name>
<name><surname>Sherman</surname><given-names>L</given-names></name>
<name><surname>Herlich</surname><given-names>PA</given-names></name>
</person-group>. <year>2003</year>. <article-title>CD44: from adhesion molecules to signaling receptors</article-title>. <source>Nat Rev Mol Cell Biol</source>. <volume>4</volume>:<fpage>33</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr77-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Puré</surname><given-names>E</given-names></name>
<name><surname>Assoian</surname><given-names>RK</given-names></name>
</person-group>. <year>2009</year>. <article-title>Rheostatic signaling by CD44 and hyaluronan</article-title>. <source>Cell Signal</source>. <volume>21</volume>:<fpage>651</fpage>–<lpage>655</lpage>.</citation>
</ref>
<ref id="bibr78-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rada</surname><given-names>JA</given-names></name>
<name><surname>Cornuet</surname><given-names>PK</given-names></name>
<name><surname>Hassell</surname><given-names>JR</given-names></name>
</person-group>. <year>1993</year>. <article-title>Regulation of corneal collagen fibrillogenesis in vitro by corneal proteoglycans (lumican and decorin) core proteins</article-title>. <source>Exp Eye Res</source>. <volume>56</volume>:<fpage>635</fpage>–<lpage>648</lpage>.</citation>
</ref>
<ref id="bibr79-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rah</surname><given-names>MJ</given-names></name>
</person-group>. <year>2011</year>. <article-title>A review of hyaluronan and its ophthalmic applications</article-title>. <source>Optometry</source>. <volume>82</volume>:<fpage>38</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr80-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rapraeger</surname><given-names>AC</given-names></name>
<name><surname>Krufka</surname><given-names>A</given-names></name>
<name><surname>Olwin</surname><given-names>BB</given-names></name>
</person-group>. <year>1991</year>. <article-title>Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation</article-title>. <source>Science</source>. <volume>252</volume>:<fpage>1705</fpage>–<lpage>1708</lpage>.</citation>
</ref>
<ref id="bibr81-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reed</surname><given-names>CC</given-names></name>
<name><surname>Iozzo</surname><given-names>RV</given-names></name>
</person-group>. <year>2002</year>. <article-title>The role of decorin in collagen fibrillogenesis and skin homeostasis</article-title>. <source>Glycoconj J</source>. <volume>19</volume>:<fpage>249</fpage>–<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr82-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rhiner</surname><given-names>C</given-names></name>
<name><surname>Gysi</surname><given-names>S</given-names></name>
<name><surname>Frohli</surname><given-names>E</given-names></name>
<name><surname>Henegartner</surname><given-names>MO</given-names></name>
<name><surname>Hajnal</surname><given-names>A</given-names></name>
</person-group>. <year>2005</year>. <article-title>Syndecan regulates cell migration and axon guidance in <italic>C. elegans</italic></article-title>. <source>Development</source>. <volume>132</volume>:<fpage>4621</fpage>–<lpage>4633</lpage>.</citation>
</ref>
<ref id="bibr83-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ricciardelli</surname><given-names>C</given-names></name>
<name><surname>Sakko</surname><given-names>AJ</given-names></name>
<name><surname>Ween</surname><given-names>MP</given-names></name>
<name><surname>Russell</surname><given-names>DL</given-names></name>
<name><surname>Horsfall</surname><given-names>DJ</given-names></name>
</person-group>. <year>2009</year>. <article-title>The biological role and regulation of versican levels in cancer</article-title>. <source>Cancer Metastasis Rev</source>. <volume>28</volume>:<fpage>233</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr84-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richardson</surname><given-names>TP</given-names></name>
<name><surname>Trinkaus-Randall</surname><given-names>V</given-names></name>
<name><surname>Nugent</surname><given-names>MA</given-names></name>
</person-group>. <year>2001</year>. <article-title>Regulation of heparan sulfate proteoglycan nuclear localization by fibronectin</article-title>. <source>J Cell Sci</source>. <volume>114</volume>:<fpage>1613</fpage>–<lpage>1623</lpage>.</citation>
</ref>
<ref id="bibr85-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ringvall</surname><given-names>M</given-names></name>
<name><surname>Ledin</surname><given-names>J</given-names></name>
<name><surname>Holmborn</surname><given-names>K</given-names></name>
<name><surname>van Kuppevelt</surname><given-names>T</given-names></name>
<name><surname>Ellin</surname><given-names>F</given-names></name>
<name><surname>Eriksson</surname><given-names>I</given-names></name>
<name><surname>Olofsson</surname><given-names>AM</given-names></name>
<name><surname>Kjellén</surname><given-names>L</given-names></name>
<name><surname>Forsberg</surname><given-names>E</given-names></name>
</person-group>. <year>2000</year>. <article-title>Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking <italic>N</italic>-deacetylase/<italic>N</italic>-sulfotransferase-1</article-title>. <source>J Biol Chem</source>. <volume>275</volume>:<fpage>25926</fpage>–<lpage>25930</lpage>.</citation>
</ref>
<ref id="bibr86-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rönnberg</surname><given-names>E</given-names></name>
<name><surname>Melo</surname><given-names>FR</given-names></name>
<name><surname>Pejler</surname><given-names>G</given-names></name>
</person-group>. <year>2012</year>. <article-title>Mast cell proteoglycans</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>950</fpage>–<lpage>962</lpage>.</citation>
</ref>
<ref id="bibr87-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosen</surname><given-names>SD</given-names></name>
<name><surname>Lemjabbar-Alaoui</surname><given-names>H</given-names></name>
</person-group>. <year>2010</year>. <article-title>Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate</article-title>. <source>Expert Opin Ther Targets</source>. <volume>14</volume>:<fpage>935</fpage>–<lpage>949</lpage>.</citation>
</ref>
<ref id="bibr88-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saksela</surname><given-names>O</given-names></name>
<name><surname>Moscatelli</surname><given-names>D</given-names></name>
<name><surname>Sommer</surname><given-names>A</given-names></name>
<name><surname>Rifkin</surname><given-names>DB</given-names></name>
</person-group>. <year>1988</year>. <article-title>Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation</article-title>. <source>J Cell Biol</source>. <volume>107</volume>:<fpage>743</fpage>–<lpage>751</lpage>.</citation>
</ref>
<ref id="bibr89-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanderson</surname><given-names>RD</given-names></name>
<name><surname>Iozzo</surname><given-names>RV</given-names></name>
</person-group>. <year>2012</year>. <article-title>Targeting heparanase for cancer therapy at the tumor-matrix interface</article-title>. <source>Matrix Biol</source>. <volume>31</volume>:<fpage>283</fpage>–<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr90-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sangaard</surname><given-names>KW</given-names></name>
<name><surname>Sonne-Schmidt</surname><given-names>CS</given-names></name>
<name><surname>Krogager</surname><given-names>TP</given-names></name>
<name><surname>Lorentzen</surname><given-names>KA</given-names></name>
<name><surname>Wisniewski</surname><given-names>HG</given-names></name>
<name><surname>Thørgersen</surname><given-names>IB</given-names></name>
<name><surname>Enghild</surname><given-names>JJ</given-names></name>
</person-group>. <year>2008</year>. <article-title>The transfer of heavy chains from bikunin proteins to hyaluronan requires both TSG-6 and HC-2</article-title>. <source>J Biol Chem</source>. <volume>283</volume>:<fpage>18530</fpage>–<lpage>18537</lpage>.</citation>
</ref>
<ref id="bibr91-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saper</surname><given-names>CB</given-names></name>
</person-group>. <year>2009</year>. <article-title>A guide to the perplexed on the specificity of antibodies</article-title>. <source>J Histochem Cytochem</source>. <volume>57</volume>:<fpage>1</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr92-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schlessinger</surname><given-names>J</given-names></name>
<name><surname>Plotnikov</surname><given-names>AN</given-names></name>
<name><surname>Ibrahmi</surname><given-names>OA</given-names></name>
<name><surname>Eliseenkova</surname><given-names>AV</given-names></name>
<name><surname>Yeh</surname><given-names>BK</given-names></name>
<name><surname>Yayon</surname><given-names>A</given-names></name>
<name><surname>Linhardt</surname><given-names>RJ</given-names></name>
<name><surname>Mohammadi</surname><given-names>M</given-names></name>
</person-group>. <year>2000</year>. <article-title>Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization</article-title>. <source>Mol Cell</source>. <volume>6</volume>:<fpage>743</fpage>–<lpage>750</lpage>.</citation>
</ref>
<ref id="bibr93-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shintani</surname><given-names>Y</given-names></name>
<name><surname>Takashima</surname><given-names>S</given-names></name>
<name><surname>Asano</surname><given-names>Y</given-names></name>
<name><surname>Kato</surname><given-names>H</given-names></name>
<name><surname>Liao</surname><given-names>Y</given-names></name>
<name><surname>Yamazaki</surname><given-names>S</given-names></name>
<name><surname>Tsukamoto</surname><given-names>O</given-names></name>
<name><surname>Seguchi</surname><given-names>O</given-names></name>
<name><surname>Yamamoto</surname><given-names>H</given-names></name>
<name><surname>Fukushima</surname><given-names>T</given-names></name>
<etal/></person-group>. <year>2006</year>. <article-title>Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling</article-title>. <source>EMBO J</source>. <volume>25</volume>:<fpage>3045</fpage>–<lpage>3055</lpage>.</citation>
</ref>
<ref id="bibr94-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siiskonen</surname><given-names>H</given-names></name>
<name><surname>Törrönen</surname><given-names>K</given-names></name>
<name><surname>Kumlin</surname><given-names>T</given-names></name>
<name><surname>Rilla</surname><given-names>K</given-names></name>
<name><surname>Tammi</surname><given-names>MI</given-names></name>
</person-group>. <year>2011</year>. <article-title>Chronic UVR causes increased immunostaining of CD44 and accumulation of hyaluronan in mouse epidermis</article-title>. <source>J Histochem Cytochem</source>. <volume>59</volume>:<fpage>908</fpage>–<lpage>917</lpage>.</citation>
</ref>
<ref id="bibr95-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>RA</given-names></name>
<name><surname>Meade</surname><given-names>K</given-names></name>
<name><surname>Pickford</surname><given-names>CE</given-names></name>
<name><surname>Holley</surname><given-names>RJ</given-names></name>
<name><surname>Merry</surname><given-names>CL</given-names></name>
</person-group>. <year>2011</year>. <article-title>Glycosaminoglycans as regulators of stem cell differentiation</article-title>. <source>Biochem Soc Trans</source>. <volume>39</volume>:<fpage>383</fpage>–<lpage>387</lpage>.</citation>
</ref>
<ref id="bibr96-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stanton</surname><given-names>H</given-names></name>
<name><surname>Melrose</surname><given-names>J</given-names></name>
<name><surname>Little</surname><given-names>CB</given-names></name>
<name><surname>Fosang</surname><given-names>AJ</given-names></name>
</person-group>. <year>2011</year>. <article-title>Proteoglycan degradation by the ADAMTS family of proteinases</article-title>. <source>Biochim Biophys Acta</source>. <volume>1812</volume>:<fpage>1616</fpage>–<lpage>1629</lpage>.</citation>
</ref>
<ref id="bibr97-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stattin</surname><given-names>EL</given-names></name>
<name><surname>Wiklund</surname><given-names>F</given-names></name>
<name><surname>Lindblom</surname><given-names>K</given-names></name>
<name><surname>Onnerfjord</surname><given-names>P</given-names></name>
<name><surname>Jonsson</surname><given-names>BA</given-names></name>
<name><surname>Tegner</surname><given-names>Y</given-names></name>
<name><surname>Sasaki</surname><given-names>T</given-names></name>
<name><surname>Struglics</surname><given-names>A</given-names></name>
<name><surname>Lohmander</surname><given-names>S</given-names></name>
<name><surname>Dahl</surname><given-names>N</given-names></name>
<etal/></person-group>. <year>2010</year>. <article-title>A missense mutation in the aggrecan C-type lectin domain disrupts extracellular matrix interactions and causes dominant familial osteochondritis dissecans</article-title>. <source>Am J Hum Genet</source>. <volume>86</volume>:<fpage>126</fpage>–<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr98-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Subbaiah</surname><given-names>VK</given-names></name>
<name><surname>Kranjec</surname><given-names>C</given-names></name>
<name><surname>Thomas</surname><given-names>M</given-names></name>
<name><surname>Banks</surname><given-names>L</given-names></name>
</person-group>. <year>2011</year>. <article-title>PDZ domain: the building blocks regulating tumorigenesis</article-title>. <source>Biochem J</source>. <volume>439</volume>:<fpage>195</fpage>–<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr99-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tamm</surname><given-names>C</given-names></name>
<name><surname>Kjellén</surname><given-names>L</given-names></name>
<name><surname>Li</surname><given-names>J-P</given-names></name>
</person-group>. <year>2012</year>. <article-title>Heparan sulfate biosynthesis enzymes in embryonic stem cell biology</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>943</fpage>–<lpage>949</lpage>.</citation>
</ref>
<ref id="bibr100-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tammi</surname><given-names>RH</given-names></name>
<name><surname>Passi</surname><given-names>AG</given-names></name>
<name><surname>Rilla</surname><given-names>K</given-names></name>
<name><surname>Karousou</surname><given-names>E</given-names></name>
<name><surname>Vignetti</surname><given-names>D</given-names></name>
<name><surname>Makkonen</surname><given-names>K</given-names></name>
<name><surname>Tammi</surname><given-names>MI</given-names></name>
</person-group>. <year>2011</year>. <article-title>Transcriptional and post-translational regulation of hyaluronan synthesis</article-title>. <source>FEBS J</source>. <volume>278</volume>:<fpage>1419</fpage>–<lpage>1428</lpage>.</citation>
</ref>
<ref id="bibr101-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Teng</surname><given-names>YH</given-names></name>
<name><surname>Aquino</surname><given-names>RS</given-names></name>
<name><surname>Park</surname><given-names>PW</given-names></name>
</person-group>. <year>2012</year>. <article-title>Molecular functions of syndecan-1 in disease</article-title>. <source>Matrix Biol</source>. <volume>31</volume>:<fpage>3</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr102-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Traister</surname><given-names>A</given-names></name>
<name><surname>Shi</surname><given-names>W</given-names></name>
<name><surname>Filmus</surname><given-names>J</given-names></name>
</person-group>. <year>2008</year>. <article-title>Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface</article-title>. <source>Biochem J</source>. <volume>410</volume>:<fpage>503</fpage>–<lpage>511</lpage>.</citation>
</ref>
<ref id="bibr103-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Troeberg</surname><given-names>L</given-names></name>
<name><surname>Nagase</surname><given-names>H</given-names></name>
</person-group>. <year>2012</year>. <article-title>Proteases involved in cartilage matrix degradation in osteoarthritis</article-title>. <source>Biochim Biophys Acta</source>. <volume>1824</volume>:<fpage>133</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr104-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>SM</given-names></name>
<name><surname>Fernig</surname><given-names>DG</given-names></name>
<name><surname>Jesudason</surname><given-names>EC</given-names></name>
<name><surname>Losty</surname><given-names>PD</given-names></name>
<name><surname>van de Westerlo</surname><given-names>EMA</given-names></name>
<name><surname>van Kuppevelt</surname><given-names>TH</given-names></name>
<name><surname>Turnbull</surname><given-names>JE</given-names></name>
</person-group>. <year>2009</year>. <article-title>Heparan sulfate phage display antibodies identify distinct epitopes with complex binding characteristics</article-title>. <source>J Biol Chem</source>. <volume>284</volume>:<fpage>35621</fpage>–<lpage>35631</lpage>.</citation>
</ref>
<ref id="bibr105-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Valayannopoulos</surname><given-names>V</given-names></name>
<name><surname>Wijburg</surname><given-names>FA</given-names></name>
</person-group>. <year>2011</year>. <article-title>Therapy for the mucopolysaccharidoses</article-title>. <source>Rheumatology (Oxford)</source>. <volume>50</volume>:<fpage>v49</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr106-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van Kuppevelt</surname><given-names>TH</given-names></name>
<name><surname>Dennissen</surname><given-names>MABA</given-names></name>
<name><surname>van Venrooij</surname><given-names>WJ</given-names></name>
<name><surname>Hoet</surname><given-names>RMA</given-names></name>
<name><surname>Veerkamp</surname><given-names>JH</given-names></name>
</person-group>. <year>1998</year>. <article-title>Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology</article-title>. <source>J Biol Chem</source>. <volume>273</volume>:<fpage>12960</fpage>–<lpage>12966</lpage>.</citation>
</ref>
<ref id="bibr107-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Váradi</surname><given-names>T</given-names></name>
<name><surname>Mersich</surname><given-names>T</given-names></name>
<name><surname>Auvinen</surname><given-names>P</given-names></name>
<name><surname>Tammi</surname><given-names>R</given-names></name>
<name><surname>Tammi</surname><given-names>M</given-names></name>
<name><surname>Salamon</surname><given-names>F</given-names></name>
<name><surname>Besznyák</surname><given-names>I</given-names></name>
<name><surname>Jakab</surname><given-names>F</given-names></name>
<name><surname>Baranyai</surname><given-names>Z</given-names></name>
<name><surname>Szöllősi</surname><given-names>J</given-names></name>
<etal/></person-group>. <year>2012</year>. <article-title>Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>567</fpage>–<lpage>575</lpage>.</citation>
</ref>
<ref id="bibr108-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>A</given-names></name>
<name><surname>Hascall</surname><given-names>VC</given-names></name>
</person-group>. <year>2009</year>. <article-title>Hyperglycaemia, intracellular hyaluronan synthesis, cyclin D3 and autophagy</article-title>. <source>Autophagy</source>. <volume>5</volume>:<fpage>864</fpage>–<lpage>865</lpage>.</citation>
</ref>
<ref id="bibr109-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>A</given-names></name>
<name><surname>de</surname><given-names>al</given-names></name>
<name><surname>Motte</surname><given-names>CA</given-names></name>
<name><surname>Lauer</surname><given-names>M</given-names></name>
<name><surname>Hascall</surname><given-names>VC</given-names></name>
</person-group>. <year>2011</year>. <article-title>Hyaluronan matrices in pathobiological processes</article-title>. <source>FEBS J</source>. <volume>278</volume>:<fpage>1412</fpage>–<lpage>1418</lpage>.</citation>
</ref>
<ref id="bibr110-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Q</given-names></name>
<name><surname>Teder</surname><given-names>P</given-names></name>
<name><surname>Judd</surname><given-names>NP</given-names></name>
<name><surname>Noble</surname><given-names>PW</given-names></name>
<name><surname>Poerschuk</surname><given-names>CM</given-names></name>
</person-group>. <year>2002</year>. <article-title>CD44 deficiency leads to enhanced neutrophil migration and lung injury in <italic>Escherichia coli</italic> pneumonia in mice</article-title>. <source>Am J Pathol</source>. <volume>161</volume>:<fpage>2219</fpage>–<lpage>2228</lpage>.</citation>
</ref>
<ref id="bibr111-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ween</surname><given-names>MP</given-names></name>
<name><surname>Oehler</surname><given-names>MK</given-names></name>
<name><surname>Ricciardelli</surname><given-names>C</given-names></name>
</person-group>. <year>2011</year>. <article-title>Role of versican, hyaluronan and CD44 in ovarian cancer metastasis</article-title>. <source>Int J Mol Sci</source>. <volume>12</volume>:<fpage>1009</fpage>–<lpage>1029</lpage>.</citation>
</ref>
<ref id="bibr112-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamaguchi</surname><given-names>Y</given-names></name>
</person-group>. <year>2000</year>. <article-title>Lecticans: organizers of the brain extracellular matrix</article-title>. <source>Cell Mol Life Sci</source>. <volume>57</volume>:<fpage>276</fpage>–<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr113-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoneda</surname><given-names>A</given-names></name>
<name><surname>Lendorf</surname><given-names>ME</given-names></name>
<name><surname>Couchman</surname><given-names>JR</given-names></name>
<name><surname>Multhaupt</surname><given-names>HAB</given-names></name>
</person-group>. <year>2012</year>. <article-title>Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans</article-title>. <source>J Histochem Cytochem</source>. <volume>60</volume>:<fpage>9</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr114-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>S</given-names></name>
<name><surname>He</surname><given-names>H</given-names></name>
<name><surname>Day</surname><given-names>AJ</given-names></name>
<name><surname>Tseng</surname><given-names>SC</given-names></name>
</person-group>. <year>2012</year>. <article-title>Constitutive expression of inter-α-inhibitor (IαI) family proteins and tumor necrosis factor–stimulated gene-6 (TSG-6) by human amniotic membrane epithelial and stromal cells supporting formation of the heavy chain-hyaluronan (HC-HA) complex</article-title>. <source>J Biol Chem</source>. <volume>287</volume>:<fpage>12433</fpage>–<lpage>12444</lpage>.</citation>
</ref>
<ref id="bibr115-0022155412464638">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhuo</surname><given-names>L</given-names></name>
<name><surname>Yamada</surname><given-names>M</given-names></name>
<name><surname>Zhao</surname><given-names>M</given-names></name>
<name><surname>Yingsung</surname><given-names>W</given-names></name>
<name><surname>Yoshida</surname><given-names>N</given-names></name>
<name><surname>Kitagawa</surname><given-names>Y</given-names></name>
<name><surname>Kawamura</surname><given-names>K</given-names></name>
<name><surname>Suzuki</surname><given-names>T</given-names></name>
<name><surname>Kimata</surname><given-names>K</given-names></name>
</person-group>. <year>2001</year>. <article-title>Defect in SHAP-hyaluronan complex causes severe female infertility: a study by inactivation of the bikunin gene in mice</article-title>. <source>J Biol Chem</source>. <volume>276</volume>:<fpage>7693</fpage>–<lpage>7696</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>